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Background: Home care is an important care setting for those with Alzheimer’s disease 
(AD). It provides support that allows individuals with AD to remain at home and may 
delay the transition to long-term care homes. Many clients with AD receive medications 
that are used for managing the symptoms of AD: cholinesterase inhibitors (ChEIs) and 
memantine. Ontario’s provincial drug benefit plan (ODB) provides subsidies for some of 
these medications based on specific clinical criteria. These AD medications are costly 
and can have significant side effects, so it is important to understand how they are being 
used in practice.  
 
Objectives: The objectives of this study were to report the proportion taking AD 
medications and which types were taken, show the change in receipt of AD medications 
over time, and show the covariates that were independently associated with receiving 
AD medications. 
 
Methods: Analysis of secondary data was performed on the provincial home care 
dataset. All home care clients receiving long-term home care services were assessed 
using the RAI-Home Care (RAI-HC), which is a comprehensive and standardized 
assessment. One assessment from each individual over the age of 65 who was assessed 




Results: Overall, 65% of clients with a diagnosis of AD were receiving an AD medication. 
Logistic regression analysis among those diagnosed with AD showed that increased 
physical impairment and clinical complexity were associated with decreased odds of 
receiving AD medication. Contraindicating diagnoses such as congestive heart failure, 
lack of medical oversight and needing to make economic tradeoffs were also associated 
with decreased odds of receiving AD medication.  
 
Conclusions: The multivariate model showed trends of rational prescribing, such as 
clients with contraindicating diagnoses or very high clinical complexity having decreased 
odds of receiving AD medications. At the same time, evidence of structural barriers to 
receiving the medications was shown. There is debate about the cost-effectiveness of 
these medications. The provincial government could consider expanding ODB guidelines 
to include all AD medications for those with all levels of cognitive impairment, but 
further analyses involving longitudinal outcomes available in this dataset should be 
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1 Introduction and Overview 
 
Alzheimer’s disease (AD) is a progressive and degenerative disease of the brain that is 
the most prevalent form of dementia in older adults (Lindsay et al., 2004). It is generally 
slow in onset and progresses from forgetfulness to decreased ability to perform every-
day tasks, inability to safely care for oneself and lack of awareness of people and 
surroundings. AD is sometimes accompanied by behavioural changes such as agitation, 
aggression and depression (McKhann et al., 1984). It is an important disease to study 
and understand because it has a large impact on health from levels of the individual and 
caregiver(s) to the health care system and society. 
 
AD is a very difficult disease to live with because of the loss of memory and judgement 
in affected persons, but it is also very difficult for the caregiver. Informal caregivers can 
spend an average of 35 hours a week caring for someone with severe AD (Moore, Zhu & 
Clipp, 2001). A person with other chronic diseases may need more personal support, but 
they are able to appreciate and acknowledge the help they are receiving. It is also of 
great importance to the health care system because of the long duration of the disease 
and the cost of providing care to those affected by it. The cost to society as a whole with 
stress and lost time for caregivers is also significant, not to mention the costs associated 




The Canadian Study of Health and Aging found that 8% of those over 65 have dementia, 
but the proportions were not equal in subsets of that population. Dementia was found 
in 2.4% of those between 65 and 74, 11.1% of those between 75 and 84 and 34.5% of 
those over 85, and almost two-thirds of these cases were AD (Lindsay et al., 2004). This 
is particularly alarming in light of the aging population. By 2050, the number of people 
with AD is projected to quadruple, and even a major breakthrough in medications that 
would delay the onset of AD by six months would still result in a three-fold increase in 
those with AD by 2050 (Sloane et al., 2002).  
 
As the health care system moves toward accommodating Canadians’ desire to stay in 
their own homes for as long as possible, many more people with AD will receive home 
care services to delay the transition to residential care facilities. Therefore, home care is 
an important sector of Ontario’s health care continuum. Home care provides health 
services in a person’s home that they might otherwise need to be in a hospital or a 
nursing home to receive. Home care was referred to as the “next essential service” in 
Roy Romanow’s report on the state of Canadian health care (Romanow, 2002). Home 
care continues to be a priority in Ontario as shown by the provincial government’s $1.1 
billion dollar “Aging at Home” strategy which provides funding for locally initiated small 
and large scale projects designed to help people stay in their own homes (Ministry of 




Cholinesterase inhibitor (ChEI) medications and memantine are first choice 
pharmacotherapies for AD. According to the Canadian Consensus guidelines, there is 
evidence for modest effects of ChEIs when prescribed in mild to moderate AD and 
evidence for use of both ChEIs and memantine in moderate to severe AD (Herrmann, 
Gauthier & Lysy, 2007; Hogan et al., 2007). These medications are expensive. In 2002, 
ChEIs accounted for 25% of the mental health-related drug costs while representing less 
than 6% of mental health related drug prescriptions (Mamdani et al., 2005). Currently, 
the cost of ChEIs in Ontario is almost five dollars per day, which translates into about 
$1,600 per person per year (Ministry of Health and Long-Term Care, 2007b) so the cost-
effectiveness of these medications given their modest effects is an important 
consideration. 
 
AD is of particular interest in home care, because supervision and safety precautions can 
vary widely and there is a growing trend toward helping people stay at home longer. In 
Ontario, of the approximately 1.6 million people over 65 years of age, about 8% are 
receiving long-term home care services (Lindsay et al., 2004; Statistics Canada, 2007) 
 
The literature review will give an overview of home care and AD, and provide 
background on the mechanisms, indications, evidence for use, regulatory framework 
and utilization of the ChEIs and memantine in Ontario. Additionally, prevalence and 
patterns of use of these medications will be explored and individual characteristics 
predicting use of these medications will also be examined. 
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2 Literature Review 
2.1 Home Care  
 
In Roy Romanow’s 2002 report, home care is described as the next essential service for 
the Canadian healthcare system (Romanow, 2002). Home care provides services that 
allow clients to return home more quickly from hospital or stay at home longer before 
moving to a residential care setting. It has become an increasingly important part of the 
health care continuum across Canada. Currently about 900,000 Canadians are receiving 
some form of home care services and the majority of clients are 65 or older and require 
long-term supportive care  (Canadian Home Care Association, 2008). All ten provinces 
and three territories provide home care to their residents and acknowledge that home 
care is an important part of primary care, chronic disease management and aging at 
home strategies. These strategies are intended to ease the current burden on the 
existing inpatient and residential care facilities and prepare for a future where demand 
for health care services will increase.  
 
Home care services are meant to complement assistance and support from informal 
caregivers such as family members and friends and can include personal support such as 
bathing or dressing, or nursing services such as wound care or intravenous medications. 
Because home care is categorized under ‘extended health services’ in the Canada Health 
Act, it is not an insured health service. Each province and territory has their own Act, set 
of guidelines, or policies that direct the delivery of home care services according to the 
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needs of their population. This contributes to the variations in access and availability of 
services across the country. 
 
In Ontario, home care services are accessed through the 14 Community Care Access 
Centres (CCACs), which determine a person’s eligibility for funded services and provide 
case management for a variety of services contracted from provider agencies. They 
share the same geographic boundaries as the 14 recently created Local Health 
Integration Networks (LHINs) (See Appendix A for a map). The vast majority of clients 
who receive services receive them in a private home, but some may receive them while 
living in a long term care home, assisted living or supportive housing facility. One type of 
home care service recipient is a placement client, who is assessed in the hospital with 
the intent to place them in a Long Term Care Home (LTCH). Post-acute clients are those 
coming home from the hospital who need some short term nursing care such as 
dressing changes and IV medications. However, the majority are long-stay clients who 
are expected to be on service for 60 days or longer and tend to require services such as 
personal support, homemaking, and help with bathing.  
2.2 Alzheimer’s Disease 
 
AD was first identified as a pathological condition in 1906 by Alois Alzheimer. He 
described the plaques and tangles in the brain that are now accepted as the hallmark of 
the disease  (Alzheimer, 1906; Maurer, Volk & Gerbaldo, 1997). It is diagnosed by using 
clinical criteria to identify AD as well as by excluding other diseases that could cause the 
symptoms that the person is exhibiting. These diseases include Parkinson’s disease, or 
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other forms of dementia such as vascular or Lewy body dementias (Bouchard, 2007; 
Patterson et al., 1999). Familial AD, which is a rare subtype of AD, can be diagnosed by 
investigating if there are gene mutations in genes such as  presenilins 1 and 2, but other 
genetic markers, such as the E4 allele of apolipoprotein E are only associated with an 
increased risk of developing AD (Blennow, de Leon & Zetterberg, 2006).  
 
 There are two different sets of clinical criteria currently in use for diagnosing AD. The 
Diagnostic and Statistical Manual (4th ed.) (DSM-IV) describes dementia as 
“characterized by impaired memory and at least one of the following cognitive 
disturbances: aphasia, apraxia, agnosia, and disturbed executive function.” To diagnose 
AD specifically, the dementia criteria should be present, as well as evidence of insidious 
onset and progressive decline  (American Psychiatric Association, 1994). The National 
Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease 
and Related Disorders Association Work Group (NINCDS-ADRDA) have more complex 
diagnostic criteria for AD which consist of: dementia based on clinical examination and 
neuropsychological tests, with onset between ages 40 and 90, deficits in two or more 
areas of cognition, progressive worsening of memory and other cognitive functions and 
normal consciousness (McKhann et al., 1984).  
 
A clinical diagnosis can be made using the criteria outlined above, but a pathological 
diagnosis can only be made by observing the plaques and tangles directly during an 
autopsy. Possible or probable AD are the diagnoses that are most often made in 
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practice. AD is often categorized into mild, moderate, or severe based on the stage of 
the disease. It is also possible for a diagnosis of probable AD to change to a diagnosis of 
another form of dementia if other symptoms emerge (Feldman et al., 2008). For these 
reasons, making a diagnosis of AD can be difficult. 
 
2.2.1 Biological mechanisms 
 
The classic hypothesis about the biological mechanism of AD is based on the 
acetylcholine (ACh) hypothesis. In normal brain signaling, ACh is a neurotransmitter that 
carries signals from one nerve cell to another. It is released from the end of one cell and 
travels across the space between nerve cells. When it binds with its receptors on the 
next neuron, the signal is passed along (Schliebs & Arendt, 2006). The ACh is normally 
broken down by acetylcholinesterase (AChE) so that too much does not accumulate in 
the space between the nerve cells (Hardy, 2006). 
 
Bartus compiled evidence from many small studies in the late 1970s and early 1980s to 
show that significant changes in cholinergic markers were present in animal models of 
dementia (Bartus, Dean Iii, Beer & Lippa, 1982). These changes or dysfunctions were 
correlated with neuropathological markers and with the severity of cognitive 
impairments. AD was considered a cholinergic syndrome because of the selective 
degeneration of pre-synaptic cholinergic function  (Perry, Perry, Blessed & Tomlinson, 




In AD, there is a relatively selective loss of cholinergic neurons in the basal forebrain 
nuclei, which is an area of the brain that when damaged in animal studies produced 
cognitive and learning deficits (Bartus, Dean, Beer & Lippa, 1982). ACh receptor binding 
is decreased in people with AD and is correlated with decreased cognitive function 
(Nordberg, 2005).  
 
The observed cognitive deficits in those with decreased ACh receptor binding led to the 
hypothesis that increasing the availability of ACh in the brain could mitigate the 
cognitive decline associated with AD (Nordberg, 2006). 
The cascade of pathophysiological events that is triggered does not happen to all 
neurons at the same time so the neurons that remain are good targets for treatment 
(Silvestrelli, 2006). 
 
After the ACh hypothesis, the next hypotheses about the progression of AD involved 
amyloid plaques and tau tangles. These hypotheses will be further explained below, but 
it is not yet clear how the cholinergic dysfunction and the plaques and tangles work 






2.2.2 Amyloid plaques 
 
Amyloid plaques result from the accumulation of improperly processed proteins in the 
brain. The process starts with a large particle called amyloid precursor protein (APP). In 
healthy persons, the normal secretase-α enzyme cleaves the protein so that it is soluble.  
More rarely, secretase-β cleaves the APP instead and creates a protein called β-amyloid 
which is shorter and insoluble. Both are present in normal brains, but in AD there are 
very high amounts of β -amyloid. The clearing enzymes cannot keep up and are possibly 
defective. β-amyloid molecules clump together into small toxic aggregates and this is 
what forms the recognizable plaques  
(Gouras, Almeida & Takahashi, 2005; Hardy & Higgins, 1992; Nordberg, 2006; Vardy, 
Catto & Hooper, 2005). It is not clear if these amyloid plaques are a cause or simply a 
byproduct of the disease (Hardy, 2006). 
2.2.3 Tau Tangles 
 
Another pathological hallmark of AD is the presence of tau tangles within neurons. 
These tangles are paired helical filaments that impede the normal transportation of 
nutrients within the neuron  (Duara, Barker, Loewenstein & Bain, 2009). Normal tau 
helps to maintain the structure of the microtubules that transport nutrients within cells, 
but in those with AD it can become hyperphosphorylated, which changes its structure. 
This can lead to microtubule disassembly and destabilization of the neuronal 





2.2.4 Loss of cholinergic neurons 
 
Researchers are now finding interactions between the β-amyloid and tau tangle 
hypotheses. Experiments in mice show that in neurons where tau has been removed, 
the presence of β-amyloid alone does not cause degeneration, but where both are 
present, the neurons degenerate (Rapoport et al., 2002). Hypotheses about how they 
interact include the presence of β-amyloid leading to hyperphosphorylation of tau 
through oxidative stress or receptors on neuronal membranes.  The neuronal 
membrane receptor hypothesis suggests that β-amyloid binds to certain subtypes of 
acetylcholine receptors and starts a cascade of changes which leads to the activation of 
glycogen synthase kinase-3 beta (GSK-3beta). This kinase has been shown to 
phosphorylate sites on tau and create tangles (Huang & Jiang, 2009).  
 
2.3 Medications for use in those with AD  
 
Even with continued research on the underlying biology of AD, there are still no 
treatments that delay the onset or underlying progression of the disease. The two types 
of medication that are currently available are cholinesterase inhibitors (ChEIs) and 





2.3.1 Cholinesterase inhibitors (ChEIs) 
 
Once the cholinergic hypothesis was accepted as a possible explanation for the 
development of AD, attempts were made to artificially increase cholinergic 
transmission. Early animal trials used direct injection of choline or lecithin and other 
methods. These were moderately successful, but were not well tolerated in humans 
(Bartus, Dean Iii et al., 1982). The first strategy to be approved for human use was a 
medication that helped keep the acetylcholine that the body already produced working 
longer in the brain.  
 
Tacrine was the first medication approved for use in AD. It was approved in the US in 
1997. This medication was not well accepted because of problems with liver toxicity and 
other side effects, though decreased mortality was found among those in nursing 
homes with AD who received tacrine when compared to those who did not receive the 
medication (Geldmacher, 2007; Ott & Lapane, 2002). In response to the adverse events, 
Health Canada did not approve tacrine for use in Canada. The next medication to be 
developed in this ChEI group was donepezil (Birks & Harvey, 2006a). It built on the 
strengths of tacrine and did not have the same problematic side effects (Geerts & 
Grossberg, 2006).  
 
The three ChEI medications that are currently on the market in Canada are donepezil 
(brand name: Aricept, Eisai Inc and Pfizer Inc.), galantamine (brand name: Reminyl, Shire 
Pharmaceutical Inc.) and rivastigmine (brand name: Exelon, Novartis Pharmaceutical 
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Ltd). Donepezil was approved for use in Canada in 1997, while rivastigmine and 
galantamine were not available until 2000 and 2001, respectively. 
 
The three ChEIs each have a slightly different pharmacological mechanism, but they all 
have the same general effects. As described previously, in normal cholinergic 
transmission, acetylcholine travels across the space between the nerve cells and ChE is 
the enzyme that breaks down acetylcholine so that the receptors are not 
overstimulated (Hardy, 2006). During the progression of AD, some nerve cells die so 
there is less acetylcholine available to make its way to the receptors. The less 
acetylcholine there is in the space between the neurons, the less likely it is that signals 
will pass from one neuron to the next. One way to increase the amount of acetylcholine 
in that space is to stop it from being broken down. The ChEIs work by stopping ChE from 
breaking down acetylcholine. The three medications were not found to have 
significantly different efficacies in a meta-analysis involving 13 randomized controlled 




A more recent development is the N-Methyl-D-Aspartate (NMDA) receptor antagonist 
called memantine. It has a very different mechanism of action, but like the ChEIs it does 
not slow the progression of the disease (Parsons, Stoffler & Danysz, 2007). Memantine 
was approved for use in Canada in November 2004. It has been available in the United 
States and Europe since 2003 ("Alzheimer's drug approved with reservations," 2003; 
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Cosman, Boyle & Porsteinsson, 2007; Farlow, 2004). The brand name for memantine is 
Ebixa (Lundbeck Ltd.). 
 
The exact mechanism of action of memantine is not as well characterized as that of the 
ChEIs. However, it is known that memantine is an inhibitor of glutamate N-Methyl-D-
Aspartate (NMDA) receptors. These receptors are also in the brain and normally they 
are activated by glutamate and cause the nerve cell to fire. In a person with AD, there 
are elevated levels of glutamate. This can cause the neurons to fire too often, which can 
destroy them. Memantine blocks the receptors so the glutamate cannot access the 
receptor (Mobius, Stoffler & Graham, 2004).  
2.4 Indications and Contraindications for use of AD medications 
 
In Canada, Health Canada evaluates submissions from pharmaceutical companies for 
new medications and decides if the medication is approved for use in Canada. If it is to 
be approved, there are further decisions about what information goes on the label and 
what the drug can be used for. This is called the indication. Donepezil, galantamine and 
rivastigmine are indicated for use in mild-moderate AD and donepezil is also indicated 
for use in moderate-severe AD. Memantine is indicated for use in moderate-severe AD 
only. 
 
The Canadian consensus guidelines suggest that ChEIs can be used in mild-moderate AD 
(Hogan, 2007), but in mid 2007 Health Canada agreed to expand the indication for 
donepezil to include severe AD (Health Canada, 2007b). There have also been some 
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reports of ChEIs and memantine being used for vascular and Lewy body types of 
dementia and in traumatic brain injury (Bourgeois, Bahadur & Minjares, 2002; Kaye et 
al., 2003; McKeith et al., 2000; Wilkinson et al., 2003).  
 
The only true contraindication for the cholinesterase inhibitors is hypersensitivity or 
previous adverse events related to the drugs themselves. However, caution should be 
taken when prescribing to those with coronary artery disease and congestive heart 
failure because they may slow the heart rate (Gill et al., 2009); and those with 
unexplained syncope should also not receive them (Hogan et al., 2008). ChEIs may be 
expected to increase gastric acid secretion, so when prescribed to those at high risk of 
developing ulcers, careful monitoring should occur. Those with asthma or obstructive 
pulmonary disease should also be closely monitored as higher levels of acetylcholine can 
increase inflammation in the airway (Canadian Pharmacists Association, 2007). 
Rivastigmine has not been tested in those with severe liver or renal impairment, so it is 
contraindicated in those individuals (Canadian Pharmacists Association, 2005). Weight 
loss is associated with both AD (White, Pieper & Schmader, 1998) and with ChEIs so 
careful monitoring of weight should be done for those where it is a concern (Canadian 
Pharmacists Association, 2008). Memantine has fewer systemic effects, so 
gastrointestinal and respiratory effects are not of particular concern, but caution should 





Other medications can have an impact on how effective ChEIs can be. Anticholinergics, 
which are often used to help with urinary incontinence, have the opposite effect of 
ChEIs as they decrease the amount of acetylcholine available. These medications should 
never be used in those who are taking a ChEI (Han et al., 2001). Benzodiazepine 
medications are also sometimes used to deal with behavioural issues in those with AD, 
but they are also potentially inappropriate for use in those who are taking a ChEI 
because they can cause cognitive impairment (Gray, Lai & Larson, 1999).  
2.4.1 Selected outcome measurements 
 
It is important to understand the outcome measurements used in clinical trials to 
measure the efficacy of the medications. The Mini-Mental State Exam (MMSE) is the 
most commonly used scale, and is intended to measure cognitive functioning (Folstein, 
Folstein & McHugh, 1975). The MMSE evaluates cognitive functioning in five domains 
(attention and calculation, orientation, immediate recall, delayed recall, and language). 
It usually takes 10 minutes to perform, and results in scores ranging from 0 (severely 
impaired) to 30 (normal). It is sometimes used as the cutoff in determining whether AD 
is mild, moderate or severe. Mild-moderate disease is usually categorized as having 
MMSE scores anywhere between 10 or 11 and 24 or 26, while those with severe AD 
have MMSE scores less than 10  (Birks, 2006; Herrmann, Gauthier et al., 2007).  
 
The cognitive portion of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) is a more 
sensitive measure of cognition and was developed for use in a population with AD. It 
consists of 11 items (spoken language, comprehension of spoken language, recall of test 
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instructions, word finding, following commands, naming objects, construction, 
ideational praxis, orientation, word recall, and word recognition). The score ranges from 
0 to 70 and higher scores indicate greater impairment (Cummings, 1996; Logsdon, 1995; 
Rosen, Mohs & Davis, 1984).  
2.5 Overview of evidence for use in AD 
 
Authors from the Cochrane collaboration have produced four meta-analyses on ChEIs, 
one for each medication separately (Birks, Grimley Evans, Iakovidou & Tsolaki, 2000; 
Birks & Harvey, 2006a; Loy & Schneider, 2006), and one analyzing them concurrently 
(Birks, 2006). Overall, the evidence suggests that these medications do have a small but 
significant beneficial effect on cognitive function. 
2.5.1 Donepezil       
 
There have been several large-scale randomized controlled trials testing donepezil 
against a placebo in those with AD. Most of the studies that have been published show a 
small to moderate benefit in cognitive impairment from using the medication (Engedal 
et al., 2000; Feldman et al., 2001; Rogers et al., 1998). As these medications were 
approved and grew popular, concern grew in countries with single-payer drug plans 
(such as Canada and the UK) about the actual cost effectiveness of the medication to 
the system as a whole.  
 
In the UK, the AD2000 study was publicly funded to examine donepezil in a more real-
world situation. The authors concluded that based on outcome measures, such as delay 
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of nursing home placement or use of doctor’s visits or hospital stays, donepezil was not 
cost effective   (AD2000 Collaborative Group, 2004). However, there has been mixed 
reaction to this study. Birks (2006) decided not to include AD2000 in her Cochrane 
review because of a vastly different sample size than the investigators proposed (500 
participants instead of 3,000) and a very complicated regimen and repeated washout 
periods that make interpretation of the results very difficult.  
 
2.5.2 Galantamine, Rivastigmine   
 
Overall, galantamine and rivastigmine were also shown to provide modest 
improvements in cognition and behavior in those with AD in both mild-moderate and 
severe AD, but many fewer trials have been performed using these medications as 
compared to those using donepezil (Lanctot et al., 2003; Takeda et al., 2006).  
2.5.3 Evidence for Memantine 
 
There have been several clinical trials for memantine, most showing a positive effect on 
cognitive decline (Cosman et al., 2007; Van Dyck, Tariot, Meyers & Malca Resnick, 2007). 
A Cochrane review of clinical trials for memantine has also been published (McShane, 
Areosa Sastre & Minakaran, 2006 ). McShane concludes that memantine has a small 
beneficial effect on cognition at six months in moderate to severe AD. 
 
There is evidence for the efficacy of these medications in clinical trial settings. However, 
there is evidence that the representation of patients with dementia in clinical trials of 
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donepezil was not the same when compared to those who actually took the medication 
daily. Based on a cohort of all people receiving donepezil in Ontario, 50% to 80% of 
those that were actually taking it would have been excluded from all clinical trials 
because they were older than the upper age limit. Therefore, the small but significant 
effect demonstrated in clinical trials may not precisely reflect what might happen in the 
course of normal usage because of their older age, and presumably comorbid conditions 
that would also have led to their exclusion from the clinical trials (Evans, 1995; Gill et al., 
2004). 
2.6 Regulatory framework  
2.6.1 Canada 
 
In Canada, health care is the responsibility of the provinces but for some applications, it 
makes sense to use a more centralized approach. For approval of new drugs, the 
provinces have agreed to use the information contained in the Common Drug Review 
(CDR). Pharmaceutical companies submit information and evidence to the CDR 
committee at Health Canada that decides if the product is safe for use in Canada. The 
provinces can then use that information and decide if they will add the medication to 
their formulary, which is a list of medications that are included in a provincial drug plan 
(Kelly, Lazzaro & Peterson, 2007).  
 
Each province makes the decision about whether or not to add the medication to their 
formulary independently, taking many factors into account, including cost-effectiveness 
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- whether the costs of providing the medications are outweighed by savings in other 
areas  such as the costs of formal and informal care.  
 
There is debate on cost effectiveness for AD medications. Studies done using modeling 
techniques generally showed cost-effectiveness for medication use, but there were few 
empirical studies, and their results were inconclusive. Therefore, further large-scale 
empirical studies need to be done in order to determine if these medications are cost-
effective or not (Geldmacher, 2008; Wimo, 2004; Wimo & Norlund, 2007). 
 
2.6.2 Ontario Drug Benefit Plan 
 
In Ontario, the program that provides access to medications for those over 65 is called 
the Ontario Drug Benefit (ODB) plan. People receive subsidized medicines subject to 
their income. Some medications are provided through a program called Limited Access 
which means that certain clinical criteria need to be met in order for the medication to 
be provided. The ChEIs are such medications. In order for someone over 65 to receive 
subsidized donepezil, rivastigmine, or galantamine in Ontario, their physician needs to 
submit a form stating that their MMSE score is between 10 and 26. This form needs to 
be resubmitted after three months, and can subsequently be renewed for six month 
intervals. The medication continues to be subsidized until the person’s MMSE score 
drops below 10. The cost to the ODB is about $5.00 per day. Donepezil, rivastigmine and 




2.6.3 Drug Benefit plans in other provinces 
 
Across Canada, all those 65 years of age or older have access to subsidized drug 
programs, but access to specific drugs and the proportion covered can differ between 
provinces (Demers et al., 2008). Each province has its own formulary and rules for 
access. 
 
Rules for access to ChEIs and memantine are generally the same across provinces, with a 
few notable exceptions. Memantine is available for purchase, but is not covered under 
any provincial drug plans. ChEIs are generally available as limited access medications 
through the provincial formularies. The  criteria for access differs between provinces, 
but generally requires periodic cognitive tests showing mild-moderate disease and 
discontinues subsidized medication once a certain threshold is reached. Specific details 
for access in each province and territory are shown in Appendix B. The Canadian Rx 
Atlas does show large disparities in age standardized per capita spending on ChEIs 
between provinces. The spending in Saskatchewan is 52% lower than the national 
average, while the spending in Ontario is 30% higher than the national average. These 
differences are almost wholly due to differences in volume purchased and this could be 
attributed to the stricter criteria enforced in Saskatchewan as compared to the less 






2.7 Utilization rates of ChEIs and memantine  
 
 
Medications can be used for many different reasons. Different forces can affect the use 
of medications within a population. Regulations can make a drug available or 
unavailable in a specific jurisdiction and, within a government-funded drug plan such as 
ODB, can restrict use based on characteristics of the disease. Those with low incomes 
can benefit from the medications within the regulatory framework of the ODB, but 
those with more resources are free to purchase the medications or receive them 
through private insurance plans when they are prescribed. Physician familiarity is 
another factor that can affect utilization, as they are the ones who decide which 
medication gets prescribed. Physicians are more likely to prescribe medications that 
they are familiar with (Hillmer et al., 2006; Sondergaard, Vach, Kragstrup & Andersen, 
2009).  
 
 In Ontario there are studies that have looked at utilization of ChEIs, but none have been 
found about utilization of memantine. One  study used ODB data linked to vital statistics 
and service utilization data to create a cohort of all Ontario residents 66 years of age or 
older who had a new prescription for a ChEI (Herrmann, Gill et al., 2007). The residents 
were followed until discontinuation, death or the end of the study period. Over half of 
those who died during the study period were still taking the medication when they died. 
Only 55% discontinued the medication before the end of follow-up (31 Mar 2005). This 
study also showed that 1.9% of the total Ontario population age 66 or older were 
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initiated on ChEI therapy in the initial cohort (Herrmann, Gill et al., 2007; Lanctot & 
Herrmann, 2007). Other observational studies considering persistence of ChEI therapy 
showed that 33% to 47% of the individuals studied remained on a ChEI with no 
significant gaps in therapy at one-year after initiation (Herrmann et al., 2009; Mauskopf, 
Paramore, Lee & Snyder, 2005; Singh et al., 2005; Suh et al., 2005). Increased 
persistence was associated with greater numbers of physician visits (Herrmann, Gill et 
al., 2007; Suh et al., 2005). Sex differences in persistence were not found to be 
significant (Kogut, El-Maouche & Abughosh, 2005; Mucha et al., 2008; Suh et al., 2005; 
Sun, Lai, Lu & Chen, 2008). Older age was associated with decreased persistence in one 
study (Y. Sun et al., 2008), increased persistence in another (Kogut et al., 2005), and had 
no association in others (Mucha et al., 2008; Suh et al., 2005). However, few studies 
examined characteristics associated with persistence beyond age and sex.  
 
2.7.1 Characteristics of those who received ChEIs  
 
 
Few studies have been found to date that investigate differences in demographic, 
clinical, behavioural, physical functioning, cognitive, and regional variables and how they 
influence receipt of an AD medication in a community-based population. Therefore it is 





The vast majority of studies that have been published are randomized controlled trials, 
which artificially separate people into receipt or non-receipt groups. These trials are 
important for investigating the effects of medications, but they have strict inclusion and 
exclusion criteria which do not necessarily reflect the characteristics of those who use 
the medications in the community (Evans, 1995). In fact, investigation of a cohort of 
recipients of cholinesterase inhibitors in Ontario found that between 51% and 78%  
would have been excluded from most clinical trials based on their age or comorbidities, 
so it is important to show the characteristics of those who are receiving the medications 
as part of normal clinical practice (Gill et al., 2004). 
 
Some observational studies have been performed, but they tend to use administrative 
prescription claims databases that contain minimal clinical information such as age, 
gender and diagnoses from previous hospital discharges. These studies cannot compare 
those that are using the medications to those who are not because only those who have 
been dispensed the medications appear in the prescription claims database (Gill et al., 
2004; Herrmann, Gill et al., 2007; Mamdani et al., 2005). 
 
There are a few studies that have reported on differences between groups that receive 
AD medications and those that do not. The Aged in Home Care (AdHOC) study which 
was carried out using the RAI-HC assessment in 11 European countries found that 
individuals who were cognitively impaired, unmarried and did not have a physician 
review their medications were more likely to discontinue their medications so some of 
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these same characteristics may protect against receipt of AD medications in the Ontario 
population (Cooper et al., 2005).  
 
Using evidence from clinical trials, women were reported to be more likely to have 
adverse events, and since those who are older are less likely to have been included in 
the clinical trials, it is possible that physicians may be less likely to prescribe AD 
medications in those populations (Birks, 2006). Coronary artery disease, congestive 
heart failure, unexplained syncope, gastrointestinal disease, asthma or obstructive 
pulmonary disease, severe renal impairment, and weight loss may be expected to 
predict non-receipt of AD medications, because there are warnings against use of these 
medications in the presence of those conditions (Canadian Pharmacists Association, 
2007).  
 
Socioeconomic status could also have an impact on whether people receive AD 
medications. A study done in Quebec showed that medication utilization decreased 
when cost sharing measures were introduced to a public drug program for low-income 
residents (Blais, Couture, Rahme & LeLorier, 2003). 
 
 
Regional differences could also have an impact on receipt of AD medications. As 
mentioned previously, Ontario’s home care services are organized into 14 CCACs, which 
serve clients within geographic borders that are aligned to the borders of the 14 Local 
Health Integration Networks (LHINs). There are many differences between the LHINs 
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that could influence the receipt of services including size, both in land area and in 
population, proportion of the population that is over the age of 65, median income, 
urban/rural split, and the presence of teaching hospitals. The table showing 
characteristics of the 14 LHINs with data mostly drawn from Statistics Canada’s 
Community Health Survey can be found in Appendix C. No studies were found that 
compared the rates of AD medication use across different LHINs. Other studies have 
found differences in rates of preventive care (influenza shot, mammogram, pap smear) 
and in minimally invasive biopsy for breast cancer diagnosis between LHINs (Holloway, 
Saskin & Paszat, 2008; Wang, Nie & Upshur, 2009). However, no differences between 




Home care is an important care setting in Ontario that enables many elderly people to 
remain at home and delay the transition to long-term care homes. Many of those who 
receive home care services have a chronic disease, such as AD. There are two types of 
medications that are used for managing the symptoms of AD: ChEIs and memantine. 
According to the Canadian Consensus guidelines, all three ChEI medications are 
recommended treatments for mild to moderate AD. Donepezil and memantine are 
recommended for severe AD. Clinical trial evidence has focused on the effects of these 
medications in relatively young and healthy individuals, but population- based 
investigations using administrative prescription records show that they are being used in 
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a much older and more impaired population. These medications are fairly costly to 
taxpayers and their economic benefit to the health care system has not yet been 
established empirically. They can also have side effects for the persons receiving them, 
so it is important to understand how they are being used in practice. Those receiving 
home care services tend to be older and more impaired than the general population of 




3 Study Rationale  
 
Answering the questions proposed below will make a contribution to knowledge about 
the use of AD medications in Ontario’s home care population. An understanding can be 
gained of how widely ChEIs and memantine are used in those receiving HC services in 
Ontario, differences in characteristics between those who receive them and those who 
do not, and how utilization patterns have changed over time. 
 
Studies that investigate the use of AD medications with administrative claims databases 
(specifically the Ontario Drug Benefit (ODB) database) provide information on how 
many people in Ontario use the medications and how many discontinue them 
(Herrmann et al., 2009; Herrmann, Gill et al., 2007). However, there is little information 
on the proportion of those in specific sub-populations (such as home care) who are 
reported to have AD, and who take AD medications. The claims databases also lack 
adequate clinical information to see if those who receive the medications are different 
in some way from those that have AD and do not receive them. The overall purpose of 
this study is to fill some of the gaps outlined above.  
 
3.1 Research Questions 
The following questions will be addressed in this research: 
1. What proportion of those in home care with and without a diagnosis of AD are 
taking a ChEI or memantine? 
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2. Which types of AD medications are being taken among those with an AD 
diagnosis? 
3. Are clients with AD that score 4 or higher on the CPS scale (comparable to 10 or 
lower on the MMSE) less likely to receive AD medications than those with other 
CPS scores? 
4. How has the proportion of those taking AD medications changed from 2004-
2008? 
5. What covariates are associated with a greater likelihood of receiving an AD 
medication? 
 
3.2 Relevance of research 
 
It is important to consider past and current use of AD medications in the Ontario HC 
population to inform current decisions related to health policy and service delivery and 
to identify opportunities for future research on use of these medications.  
If the results show that a specific subpopulation is underserved (e.g., women, different 
geographic regions) and there is no body of literature that suggests that the medications 
work any differently in that population, this research can highlight a health inequality 
for health care decision makers. In addition, home care case managers could target 
groups who may benefit from an AD medication but are not receiving one with health 
education strategies to encourage them to speak with primary care clinicians about 
their treatment options. It is also possible that these medications may be overused. In 
that case, information about the prevalence of use of AD medications in subpopulations 
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4 Methods section  
4.1 Data source 
4.1.1 The RAI-HC 
 
The source of the data used for these analyses is an assessment instrument called the 
Resident Assessment Instrument for Home Care (RAI-HC) (see appendix D). This is a 
comprehensive, standardized assessment that was developed for use in the home care 
setting and consists of over 300 items. It covers many domains including cognitive and 
physical functioning, mood and behavior patterns, health conditions, and service 
utilization (Morris et al., 1997). The RAI-HC was developed by an international group of 
researchers called interRAI and is in use in many countries throughout the world 
(Bernabei, 2008). It has been found to be reliable and valid (Landi et al., 2000) and is 
intended to help caregivers create care plans by assisting them in collecting the same 
information about each client. It can also help planners at any level by allowing them to 
see the characteristics of the population they are serving and compare themselves 
accurately to other jurisdictions. interRAI has also developed other assessment 
instruments for use in different care settings that have similar core items and allow for 
comparisons across different care settings (Gray et al., 2009; Hirdes et al., 2008). 
interRAI assessments are always performed by trained assessors. These assessors are 
instructed to use the best available source to complete each item (a chart, the client, 





4.1.2 Ontario RAI-HC datacut 
 
In the Ontario home care context, there is a rich source of data based on the RAI-HC. 
Starting in 2003, the Ontario Ministry of Health and Long Term Care required that every 
person who was classified as a long-stay client (expected to receive services for 60 days 
or longer) received an initial assessment and semi-annual reassessments. One group 
that also receives RAI-HC assessments that are present in this datacut are those that are 
assessed while they are in an acute care hospital for the purposes of placement in a 
Long Term Care Home. Currently, this translates into about 150,000 assessments per 
year. The anonymized datacut used for the analyses described below was received in 
September 2008 and consists of over 900,000 records (Canadian Home Care 
Association, 2008). 
4.1.3 Analytic Sample  
 
To create the analytic sample, some exclusions were made from the dataset. Those 
under the age of 65 were excluded because they make up a small proportion of the 
long-stay home care population, but they tend to be very different than the rest of the 
population. Also, they are not eligible to receive medications through the Ontario Drug 
Benefit Program so their use of medications for AD could differ for that reason. Those 
who were in the hospital and receiving the assessment for the purpose of nursing home 
placement were excluded from the final model, but were analyzed separately in the 
other tables because they tend to have different characteristics than the community-




The RAI-HC was implemented in 2003, but CCACs did not get up to full capacity until 
2004. There were no differences in the availability of ChEI medications through the ODB 
formulary in that time period. Therefore only those that were assessed between January 
2004 and September 2008 were used in the analytic sample. For the cross-sectional 
analyses, only the first assessment on record for each unique individual was used, so as 
not to over-represent those that received service for longer periods of time. For the 
analyses that compare each year between 2004 and 2008, a different dataset was 
constructed. The same exclusion criteria were applied, but a cross-sectional dataset for 
each year was constructed independently so an individual contributed to the sample 
one time in each year that they were assessed. 
4.2 Variables 
4.2.1 Individual items 
 
All the items that were used in these analyses (with the exception of the CCAC assessing 
the client and the location of the assessment, which are administrative variables 
contained in the datacut) are from the RAI-HC (see appendix D).  The assessment is 
arranged with lettered sections, numbered items, and lettered sub-items. For example, 
behavioural symptoms is the third item in section E – Mood and Behaviour Patterns. The 
first sub-item is wandering, so the label for wandering would be e3a. In the lists of items 





The AD diagnosis variable used to categorize clients into AD or non AD groups is one of 
28 diagnosis variables listed on the RAI-HC. Assessors use their best clinical judgement 
to code these diagnoses using the most accurate, reliable and valid information source 
available. Information sources can include the client’s chart, or discharge information 
from other care settings. Assessors are trained not to indicate the presence of a 
diagnosis without an appropriate information source, so clients who have AD but have 
not yet been diagnosed would not be classified as having AD in this dataset.  
 
Demographic variables that were used included sex (bb1), approximate age (calculated 
from the date of the assessment (a1) and the month and year of the birth date (bb2a)), 
marital status (bb4), living arrangement (cc6), and if the person has had to trade off 
medical expenses for food and/or shelter (p7). 
 
Social variables included if the person’s caregiver shows signs of distress (g2a or g2c) 
and if the client or caregiver thinks that the client would be better off in a different 
living environment (o2b). 
 
Clinical variables included if the client has had a physician review their medications in 
the last six months (q3), diagnoses of the most common comorbid conditions from the 
assessment (section j) (hypertension, arthritis, diabetes, coronary artery disease, and 
cancer) as well as congestive heart failure (CHF), asthma/emphysema/chronic 
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obstructive pulmonary disease (COPD), renal failure, and bladder or bowel incontinence 
(i1a or i1b rated as ‘occasionally incontinent’ or more). 
Behavioural symptoms (verbally abusive, physically abusive, socially inappropriate, 
resists care) (e3b-e) were also included. 
 
The administrative variables used are the CCAC identifier (a map showing the CCAC 
boundaries is found in appendix A), and the location of the assessment. Most 
assessments are performed in the community with the intention of determining needs 
for initiating or continuing home-based services. However, some clients are assessed in 
the hospital as part of the admission process for long-term care homes.  
 
The medication variables were compiled into binary variables for each of the three ChEIs 
as well as for memantine using the text entered medication names in items q51a 
through q525a. Medication data are collected by the case managers while they are 
completing the rest of the assessment. All medications, both prescription and over the 
counter, that were taken in the seven days before the assessment are included. 
Subsequently, two variables were created: one that is true if any one of the three ChEIs 
is present and one that is true if ChEIs or memantine is present. Lastly, one combination 
variable was constructed with four mutually exclusive groups: ChEI and  Memantine, 
ChEI only, Memantine only, none). The dependent variable in the multivariate models 
was the variable that was coded as true if either ChEI or memantine use was recorded 




4.2.2 Summary scales 
 
A variety of embedded scales are available in the RAI-HC. These measures can be used 
cross-sectionally to summarize the person’s clinical characteristics in various domain 
areas.  The scales used in these analyses will be the Cognitive Performance Scale (CPS) 
which measures the person’s cognitive skills, the Activities of Daily Living Hierarchy scale 
(ADLH) which measures early, medium, and late loss ADLs, the Changes in Health, End 
stage disease and Signs and Symptoms scale (CHESS) which is a measure of frailty and 
instability in health, the Depression Rating Scale (DRS) which can indicate possible 
depression, and the Pain scale which measures the frequency and severity of pain.  
 
The CPS has seven levels (0-6, where 0 is cognitively intact). It uses items from the 
memory, cognitive skills for daily decision making, and communication sections as well 
as the eating ADL and has been validated against the MMSE. A score of 4 on the CPS 
correlates to an MMSE score of just under 10, the generally accepted cutoff for severe 
AD (Herrmann, Gauthier et al., 2007; Landi et al., 2000; Morris et al., 1994).  
 
The ADLH is also a seven level scale (0-6, where 0 is independent in ADLs and 6 is the 
most dependent). It is a hierarchical algorithm based on the eating, locomotion in home, 
toilet use and hygiene  ADL items from the RAI-HC (Landi et al., 2000; Morris, Fries & 




The CHESS is a six level scale (0-5, where larger values indicate increasing frailty). It uses 
symptoms that may indicate frail or unstable health such as vomiting, dehydration, 
leaving food uneaten, weight loss, shortness of breath, and edema as well as decline in 
cognitive or ADL function and end-stage disease (Hirdes, Frijters & Teare, 2003). 
 
The DRS is a 15 level scale (0-14, where larger values indicate more symptoms of 
possible depression), which has been validated against the Hamilton and Cornell 
depression scales. It uses items that indicate depression, anxiety or sad mood and a 
score of 3 or more is generally used to indicate possible depression (Burrows et al., 
2000; Martin et al., 2008). 
 
The Pain scale is a four level scale (0-3, where larger values indicate more frequent or 
intense pain), which was validated against the Visual Analogue Scale for pain. It is based 
on the items for frequency and intensity of pain (Fries et al., 2001).  
 
4.3 Statistical Analyses 
 
All statistical analyses were conducted using SAS version 9.1 software. Cross-sectional 
analyses were conducted using all home care clients from the analytic sample described 
above. 
 
Univariate analyses were performed on selected variables to describe the characteristics 
of those with and without AD among those assessed in the community and in the 
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hospital setting. Univariate analyses were also performed to describe the types of AD 
medications being taken by four mutually exclusive groups: those with AD, those with 
no AD but with other dementia, those with no dementia but a CPS score of 1 or more, 
and those with no dementia and a CPS score of 0. These groups were constructed 
separately in the community and hospital settings.  
 
Analyses were also performed to describe the distribution of CPS scores and the 
proportion receiving any AD medication among each score among those with AD in both 
community and hospital assessed clients.  A chi-square test was used to determine if 
those with CPS scores of 4-6 were less likely to receive AD medications than those with 
CPS scores of 0-3. 
 
In the year-over-year analyses, cross sectional datacuts were created as described in the 
analytic sample section above. Results for community and hospital assessed clients were 
reported separately. The proportion of clients in each of the mutually exclusive 
dementia groups that received AD medications was reported in each year that exists in 
the sample. Next, the sample was restricted only to those with AD and the proportion of 
clients receiving the different types of AD medications was reported in each year 
separately for those with CPS scores of 0-3 and 4-6. 
 
The multivariate models were constructed in the group with AD and assessed in the 
community.  The association of individual characteristics with receipt of any AD 
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medication as the outcome was investigated using binary logistic regression. 
Characteristics that had more than two categories were entered as class variables. All 
variables that were significant at the bivariate level (α=0.05) were entered into the 
multivariate model. Those that were not significant in the full model were removed one 
by one. The crude odds ratios were reported along with the adjusted odds ratios, 
maximum likelihood estimates and p-values in the final models. Three models were 
created. One included all those with AD and assessed in the community and the other 
two stratified that population by CPS score (0-3 and 4-6).  
 
4.4 Ethics Approval 
 
Ethics approval was obtained from the University of Waterloo Office of Research Ethics 




5.1 Sample characteristics 
 
The original datacut received from OACCAC contained over 900,000 assessments. After 
restricting the sample to: a) assessments performed between January 2004 and 
September 2008; b) the first assessment available for each unique individual, and c) 
those who were 65 years of age or older at the time of the assessment, the final sample 
size was 321,013. 
 
Tables 1 through 3 show the distributions of the demographic, social, clinical and 
psychological variables, as well as the scale scores for those with a diagnosis of AD 
compared to all other clients in both the community-assessed and hospital-assessed 
populations. The majority (90.2%, n=289,529) of the clients were assessed in the 
community, and similar proportions of clients had a diagnosis of AD recorded in both 
settings (7.9% in the community vs 8.5% in the hospital). Overall, those in the hospital 
had a mean age of 82.4 years (95% CI 82.3-82.5), as compared to 81.3 (95% CI 81.2-81.3) 
among those in the community.  
5.1.1 Demographics 
 
As shown in Table 1, there were higher proportions of women in both the community 






Table 1: Sample Characteristics (Demographic Variables) 








disease All Others 
Alzheimer's 
disease All Others 
   % (n) 7.9 (22,977)  92.1 (266,552)  8.5 (2,665)  91.5 (28,819)  
       
Sex (Female)  64.1 (14,727) 65.8 (175,319) 60.0 (1,600) 59.0 (17,001) 
Age Categories        
  65-74 14.1 (3,229) 21.8 (58,098) 11.2 (298) 17.7 (5,098) 
  75-84 55.3 (12,706) 46.1 (122,839) 51.3 (1,367) 44.1 (12,703) 
  85+ 30.7 (7,042) 32.1 (85,615) 37.5 (1,000) 38.2 (11,018) 
Marital Status         
  Married 49.6 (11,392) 38.7 (103,253) 41.7 (1,112) 29.9 (8,604) 
  Widowed 6.9 (1,580) 10.9 (29,082) 11.3 (300) 16.4 (4,738) 
  Other 43.5 (10,002) 50.4 (134,179) 47.0 (1,253) 53.7 (15,476) 
Living Arrangement        
  Board & Care 10.3 (2,362) 6.1 (16,197) 9.3 (247) 7.9 (2,268) 
  Facility 4.2 (956) 2.6 (6,846) 6.8 (182) 4.4 (1,262) 
  Home alone 16.8 (3,849) 36.3 (96,806) 24.9 (663) 39.1 (11,262) 
  Home others 67.7 (15,559) 54.1 (144,088) 53.4 (1,423) 42.9 (12,355) 
  Missing 0.5 (104) 0.4 (1,112) 0.6 (15) 0.8 (226) 
  Other 0.6 (147) 0.6 (1,503) 5.1 (135) 5.0 (1,446) 
          





Those with AD tended to have the smallest proportions in the youngest age group (65-
74) (14.1% and 11.2% as compared to 21.8% and 17.7%, respectively) among both the 
community and hospital assessed groups. Of those with AD and assessed in the 
community, almost 50% were married and 42.5% were widowed, but in all of the other 
three groups, a higher proportion were widowed than were married. In both 
assessment settings, those with AD were less likely to reside in a private home alone 
than those without AD. The ‘made economic tradeoffs’ item was not collected in the 
hospital assessed groups. In the community groups, the proportion who reported 
making those tradeoffs was small, but was less than half as large in the AD group (0.6%) 
as in the rest of the community population (1.3%).  
5.1.2 Summary scales 
 
As would be expected, the distribution of CPS scale scores was more heavily weighted 
towards the higher, or more impaired, end among both AD groups but the difference 
was even more pronounced in the hospital assessed group (Table 2).  Those in the 
hospital assessed group also had much more physical impairment than those in the 
community. One quarter of the hospital group had an ADL hierarchy score of 5 or 6 
(severe or very severely impaired) while only 3.3% of those with AD in the community 
scored at that level. The non-AD hospital group had over three times more clients with 





Table 2: Sample Characteristics (Summary Scales) 








disease All Others 
Alzheimer's 
disease All Others 
     
Cognitive Performance Scale 
(CPS) 
       
  0-1 8.7 (2,000) 73.2 (195,049) 3.4 (90) 37.5 (10,795) 
  2-3 69.6 (16,000) 24.1 (64,311) 58.5 (1,558) 48.4 (13,938) 
  4-6 21.7 (4,975) 2.7 (7,151) 38.2 (1,017) 14.2 (4,084) 
Activities of Daily Living 
Hierarchy (ADLH) 
       
  0-1 69.1 (15,867) 81.3 (216,532) 22.6 (601) 21.4 (6,156) 
  2-4 27.6 (6,340) 16.9 (45,004) 52.4 (1,397) 55.6 (16,014) 
  5-6 3.3 (766) 1.8 (4,883) 25.0 (667) 23.1 (6,648) 
Changes in Health End-stage 
Disease and Signs and 
Symptoms (CHESS) 
       
  0-1 60.9 (13,989) 63.9 (170,314) 26.0 (692) 34.8 (10,020) 
  2-3 36.4 (8,353) 33.8 (89,938) 65.8 (1,754) 57.7 (16,623) 
  4-5 2.7 (628) 2.3 (6,211) 8.2 (219) 7.6 (2,175) 
Depression Rating Scale (DRS)        
  0 57.7 (13,242) 66.9 (178,052) 53.2 (1,418) 56.1 (16,165) 
  1-2 25.6 (5,879) 21.2 (56,376) 29.3 (780) 27.6 (7,945) 
  3-14 16.7 (3,832) 12.0 (31,878) 17.5 (467) 16.3 (4,701) 
Pain Scale         
  0 59.8 (13,728) 35.6 (94,701) 56.0 (1,493) 42.1 (12,121) 
  1 14.2 (3,252) 12.8 (34,086) 14.6 (390) 14.2 (4,092) 
  2 22.5 (5,177) 39.0 (103,824) 26.2 (697) 35.8 (10,323) 






Just under 8% of those in hospital had CHESS scores of 4-5 while just over 2% of those in 
the community had that score. When measuring the DRS, the AD groups showed a 
higher prevalence of any depressive symptoms than the non-AD groups. The non-AD 
group in the community showed the lowest prevalence of possible depression (DRS of 3-
14). Those in both AD groups reported a higher prevalence of no pain as compared to 
the non-AD groups. 
 
5.1.3 Social and clinical variables 
 
Table 3 shows that those who were diagnosed with AD had higher rates of caregiver 
distress than others in their care setting, but overall, those who were assessed in 
hospital showed higher rates of caregiver distress than those assessed in the 
community. Similarly, the clients themselves or the caregivers of those assessed in the 
hospital were much more likely to say that the person was “better off in another living 
environment” (93.1% of those with AD, 87.5% of all others) than if they were assessed in 
the community (34.2% vs 17.2%). Just under three percent had had no medication 
review in the last 6 months in the community. The item was not collected in hospital. 
 
Incontinence (measured as at least occasionally incontinent in bladder or bowel) was 
present in 35.6% of those with AD in the community and in 64.9% of those with AD in 





Table 3: Sample Characteristics (Social and Clinical Variables) 








disease All Others 
Alzheimer's 
disease All Others 
Caregiver distress 
 
16.9 (3,878) 8.3 (22,067) 35.5 (947) 21.4 (6,150) 
Better off elsewhere 
 
34.2 (7,857) 17.2 (45,848) 93.1 (2,482) 87.5 (25,216) 
No medication review 
 
3.0 (682) 2.8 (7,581) item not collected 
Incontinence 
 
35.6 (8,176) 23.9 (63,687) 64.9 (1,730) 53.1 (15,298) 
Diagnoses        
  Hypertension 44.1 (10,125) 54.1 (144,281) 50.4 (1,342) 58.1 (16,735) 
  Arthritis 36.7 (8,421) 50.5 (134,595) 26.4 (704) 32.3 (9,299) 
  Diabetes 16.1 (3,690) 23.5 (62,649) 19.6 (521) 25.3 (7,292) 
  CAD 16.9 (3,878) 25.1 (66,796) 21.7 (578) 28.3 (8,147) 
  Cancer 7.1 (1,619) 15.6 (41,472) 9.6 (256) 14.1 (4,076) 
  CHF 6.4 (1,464) 13.3 (35,322) 9.4 (251) 17.6 (5,061) 
Behaviours        
  Wandering 13.4 (3,085) 1.5 (3,858) 21.7 (577) 6.2 (1,799) 
  Verbally abusive 11.1 (2,548) 2.2 (5,760) 10.7 (286) 4.8 (1,375) 
  Physically abusive 3.5 (809) 0.4 (1,155) 7.3 (194) 2.4 (704) 
  Socially inappropriate 5.9 (1,359) 0.9 (2,472) 11.3 (301) 4.8 (1,393) 






Table 3 also shows the five most prevalent diagnoses in the study sample. Congestive 
heart failure was also reported because of its status as a contraindication for ChEI use. 
In general, the prevalence of the reported diseases is higher for persons with AD in the 
hospital compared to those with AD in the community. For persons without AD, 
prevalence of these diseases in hospital and community settings are similar. In addition, 
the diagnoses listed here are more prevalent in the non-AD population compared to AD 
clients. 
 
All the behaviour items are more prevalent in the AD groups than the non-AD groups. In 
addition, the occurrence of these behaviours are usually highest in the hospital settings 
compared with the community. Resisting care was the most common behavior across all 
four groups (17.6% and 24.7% in the AD groups in community and hospital respectively, 





5.2 Prevalence of AD medication use 
 
In Table 4, the sample is further divided into mutually exclusive subgroups. All those with 
an AD diagnosis are in the first group, those with no AD and a diagnosis of other dementia 
are in the second group. The last two groups include those with neither diagnosis but 
consider CPS score for further differentiation into: those with any cognitive impairment 
(CPS score of 1 or more), and those with no cognitive impairment (CPS score of 0). As in 
the previous table, clients assessed in the community and those assessed in the hospital 
are reported separately. The biggest difference between the distributions of the 
subgroups in community and hospital assessed clients was in the others with no AD or 
dementia diagnosis and no cognitive impairment. Of those in the community, 51.1% were 
in that group, while only 19.7% of those in the hospital were in the no cognitive 
impairment group. 
 
The next section of the table shows the proportion within each subgroup that reported 
receiving any of the three ChEI medications, and then shows the breakdown of which 
specific medications were received. In both assessment locations, those in the AD 
subgroup showed the highest prevalence of ChEI use, but use was more common among 
those with AD in the community (66.0%) as compared to those with AD in the hospital 
(45.0%). Donepezil was by far the most popular ChEI. It was used by 42.3% of the 





Table 4: Prevalence of type of AD Medication use in different groups among Community and Hospital assessed individuals 
  Community (n=289,529) Hospital (n=31,484) 















% (n)  7.9 (22,977)   11.3 (32,628)   29.7 (86,087)   51.1 (147,801)   8.5 (2,665)   26.7 (8,402)   45.1 (14,200)   19.7 (6,216)  
Any 
Cholinesterase 
inhibitor  66.0 (15,174)   35.0 (11,404)   4.7 (4,052)   0.6 (849)   45.0 (1,199)   21.5 (1,803)   3.5 (492)   0.6 (35)  
Donepezil  42.3 (9,729)   21.5 (7,026)   2.8 (2,434)   0.3 (472)   28.6 (762)   13.2 (1,106)   2.1 (300)   0.3 (18)  
Rivastigmine  8.6 (1,966)   4.8 (1,572)   0.7 (619)   0.1 (160)   5.8 (154)   3.1 (258)   0.5 (71)   0.1 (4)  
Galantamine  15.3 (3,522)   8.7 (2,839)   1.2 (1,009)   0.2 (218)   10.8 (287)   5.3 (446)   0.9 (123)   0.2 (13)  




        




        
0  34.0 (7,803)   65.1 (21,224)   95.3 (82,035)   99.4 (146,952)   55.0 (1,466)   78.5 (6,599)   96.5 (13,708)   99.4 (6,181)  
1  65.9 (15,132)   34.9 (11,371)   4.7 (4,042)   0.6 (848)   44.8 (1,195)   21.4 (1,796)   3.5 (490)   0.6 (35)  
2  0.2 (41)   0.1 (33)   0.0 (10)   0.0 (1)   0.2 (4)   0.1 (7)   0.0 (2)   0.0 (0)  
    
 
           
Memantine  5.6 (1,293)   1.6 (519)   0.2 (133)   0.0 (11)   3.3 (89)   1.0 (83)   0.1 (8)   0.0 (1)  




        
Any ChEI or 
Memantine  67.2 (15,444)   35.4 (11,555)   4.8 (4,106)   0.6 (855)   46.2 (1,232)   21.9 (1,838)   3.5 (495)   0.6 (36)  




        




        
ChEI +Memantine  4.5 (1,023)   1.1 (368)   0.1 (79)   0.0 (5)   2.1 (56)   0.6 (1)   0.0 (5)   0.0 (0)  
ChEI only  61.6 (14,151)   33.8 (11,036)   4.6 (3,973)   0.6 (844)   42.9 (1,143)   20.9 (21)   3.4 (487)   0.6 (35)  
Memantine only  1.2 (270)   0.5 (151)   0.1 (54)   0.0 (6)   1.2 (33)   0.4 (0)   0.0 (3)   0.0 (1)  




Home care clients who received a ChEI tended to use only one. The three do have 
similar mechanisms of action so it makes sense not to use more than one of these 
medications at once.  
 
Memantine was used less often than ChEIs (5.6% in the AD in community group, 3.3% in 
the AD in hospital group), but it showed the same decreased rate of use across the 
subgroups as the ChEIs. 
 
When receipt of any ChEI or memantine was calculated, 67.2% of those in the AD in 
community group had one of those medications, compared to 46.2% of those in the AD 
in hospital group. Those without a diagnosis received these medications less than 5% of 
the time in either setting even if they had signs of impaired cognition. 
 
For the medication status variable, four mutually exclusive groups were created. ChEI 
use alone still had the highest prevalence within each subgroup. In the community AD 
group there is an interesting pattern where the majority of the clients who received 
memantine received it in combination with a ChEI (Overall 5.6% received memantine; 
4.5% received it with a ChEI, 1.2% received memantine only). This same pattern of more 
use of memantine in combination with ChEIs does occur in the hospital AD group, but 
not to the same extent. Overall 3.3% received memantine; 2.1% received it with a ChEI, 
and 1.2% received memantine only. 
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5.3 AD medication use by CPS scores 
 
Table 5 shows the CPS distribution among the community and hospital AD groups. 
Generally, the CPS scores are distributed more towards the higher end in the hospital 
group. Of those with AD in the community, 45.6% had a CPS score of 2, while 24.9% had 
the same score among those assessed in the hospital. At the most impaired, only 1.8% 
of the community group showed a CPS score of 6, while 8.3% of the hospital group had 
that score.  
 
The next table (Table 6) uses the same community and hospital AD groups, but this time 
the numbers reported are the proportions receiving any AD medication within the CPS 
category. For example, within the community group, of those with a CPS score of 0, 






Table 5: Cognitive Performance Scale (CPS) score distribution among Community and Hospital AD groups 
CPS AD in community (n=22,977), %(n) AD in Hospital (2,665), %(n) 
0 1.8 (422) 0.6 (17) 
1 6.9 (1,578) 2.7 (73) 
2 45.6 (10,480) 24.9 (664) 
3 24.0 (5,520) 33.6 (894) 
4 3.8 (879) 8.0 (214) 
5 16.0 (3,682) 21.8 (582) 












Received AD Medications  
(Community) (n=15,442), %(n) 
 Received AD Medications 
(Hospital) (n=1,232), %(n) 
0 51.7 (218) 35.3 (6) 
1 69.1 (1,090) 45.2 (33) 
2 70.4 (7,376) 53.5 (355) 
3 69.7 (3,846) 46.6 (417) 
4 62.8 (552) 42.1 (90) 
5 60.8 (2,239) 42.4 (247) 
6 29.2 (121) 38.0 (84) 
 
  
                                                     
1
 The proportions in this table are related to the numbers in each CPS group from table 5. Of the 422 




Overall, the proportions receiving AD medications were higher in the community. This 
was true for every individual CPS level, except for those with a CPS score of 6. A 
curvilinear pattern was observed in both settings, with lower proportions of those with 
CPS scores at the extreme ends of the scale receiving AD medications. A bigger drop-off 
in this curvilinear pattern was observed in the community group as compared to the 
hospital group. In the community group, 60.8% of those with a CPS score of 5 received 
AD medications and 29.2% of those with a CPS score of 6 received them. In the hospital 
group 42.4% of those with a CPS score of 5 received AD medications and 38.0% of those 
with a CPS score of 6 received them. In both settings the CPS scores with the highest 
proportion of AD medication use were 1 to 3, which corresponds to mild-moderate 
cognitive impairment. 
 
Table 7 takes the data from Table 6 and collapses the CPS score categories into two 
groups in order to answer the question of if those with CPS scores of 4-6 are less likely 
to receive AD medications than those with CPS scores of 0-3. These splits are of interest 
because they correspond to the provincial drug formulary guidelines on when ChEIs are 
intended to be covered. In both community and hospital settings a lower proportion of 
those that were most cognitively impaired received the medications (58.5% and 41.4%, 
respectively) than those that were less impaired (69.6% and 49.2%, respectively). The 
differences were tested in each setting using a chi-squared test and the p-values for 
each setting were less than 0.0001. 
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Table 7: Proportion receiving AD medications among collapsed Cognitive Performance Scale (CPS) score groups, 
Chi-Square tested 
  Community  Hospital 
CPS 0-3 69.6 (12,532) 49.2 (811) 
CPS 4-6 58.5 (2,912) 41.4 (421) 
 





5.4 AD medication use across time 
 
In Table 8 and Table 9, the proportion who received a ChEI or memantine within the 
subgroups described in Table 4 were reported by year from 2004 to 2008. Memantine 
was extremely rare in 2004 as it was only approved for use in Canada in November of 
that year, but its use increased with each year in both the community and hospital 
groups. In 2005, 4.8% of the community AD group received memantine, but by 2008, 
12.2% of that group received it. ChEI use increased only moderately across the years 
studied among the community AD group (63.4% to 69.1%), but the relative increase in 
use was more dramatic among those with other dementia (30.4% to 42.7%). In all years 





Table 8: Prevalence of ChEI and Memantine use among mutually exclusive subgroups 2004-2008 In Community Assessed Individuals 
 Community 2004 (n=97,444) 2005 (n=111,644) 2006 (n=117,399) 2007 (119,430) 2008 (104,192) 
% (n)  ChEI Memantine ChEI Memantine ChEI Memantine ChEI Memantine ChEI Memantine 
AD 63.4 (4,871) 0.8 (59) 64.8 (5,478) 4.8 (408) 66.6 (6,053) 9.4 (853) 68.4 (6,391) 10.6 (992) 69.1 (5,499) 12.2 (972) 
Other Dementia  30.4 (3,094) 0.1 (13) 33.6 (4,012) 1.2 (144) 36.8 (4,728) 2.6 (333) 39.1 (5,421) 3.0 (413) 42.7 (5,475) 3.6 (464) 
Others with CPS1+  4.0 (1,175) 0.0 (3) 4.5 (1,502) 0.1 (31) 5.1 (1,856) 0.2 (67) 5.5 (2,068) 0.3 (100) 6.3 (2,097) 0.3 (100) 







Table 9: Prevalence of ChEI and Memantine use among mutually exclusive subgroups 2004-2008 in Hospital Assessed Individuals 
Hospital  2004 (n=4,329) 2005 (n=8,047) 2006 (n=10,964) 2007 (12,191) 2008 (n=10,197) 
% (n)  ChEI Memantine ChEI Memantine ChEI Memantine ChEI Memantine ChEI Memantine 
AD 47.2 (214) 0.0 (0) 40.5 (324) 2.5 (20) 44.5 (461) 4.8 (50) 46.2 (539) 6.2 (72) 50.8 (460) 5.4 (49) 
Other Dementia 18.9 (217) 0.0 (0) 19.1 (437) 0.7 (16) 22.5 (652) 1.7 (48) 23.2 (774) 1.3 (42) 27.1 (770) 1.8 (52) 
Others with CPS1+  2.5 (48) 0.0 (0) 2.3 (84) 0.1 (2) 3.8 (188) 0.1 (3) 4.4 (231) 0.1 (7) 4.8 (208) 0.1 (6) 





In Table 10 and Table 11, only those with AD were included in the analysis. The 
proportions who received each type of medication were reported by year from 2004 to 
2008, but separately for those with CPS scores of 0-3 (Table 10) and 4-6 (Table 11). The 
most striking differences across time in the community were seen in the proportion 
receiving ChEI with memantine. Among those in the community with CPS 0-3, in 2004 
0.5% received the combination, but by 2008, 8.5% received it. Among those with CPS 4-
6, 1.0% received a ChEI and memantine in 2004 while in 2008, 14.7% received the 
combination. The difference in prevalence between 2005 and 2008 is also larger in the 
CPS 4-6 group as compared to the CPS 0-3 group in the hospital-assessed clients (1.2% 
to 2.7% in the CPS 0-3 group and 1.9% to 4.9% in the CPS 4-6 group. 
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Table 10: Prevalence of type of AD medication use in each year 2004-2008, in Community and Hospital Assessed Individuals with AD, with Cognitive Performance Scale (CPS) 
scores between 0 And 3 
 
Community Hospital 
 % (n) 2004 (n= 2005 2006 2007 2008 2004 2005 2006 2007 2008 
ChEI 
+Memantine 
0.5 (27) 3.1 (191) 6.2 (422) 7.3 (524) 8.5 (523) 0.0 (0) 1.2 (6) 2.4 (15) 2.8 (20) 2.7 (14) 
ChEI only 67.0 (3,666) 64.9 (3,971) 63.1 (4,331) 63.4 (4,552) 62.4 (3,833) 48.5 (130) 44.1 (216) 44.6 (279) 44.5 (313) 54.8 (283) 
Memantine 
only 
0.1 (3) 0.9 (54) 1.7 (119) 1.9 (133) 2.0 (125) 0.0 (0) 0.4 (2) 2.4 (15) 1.1 (8) 1.2 (6) 
None 32.4 (1,774) 31.1 (1,899) 29.1 (1,995) 27.5 (1,973) 27.1 (1,665) 51.5 (138) 54.3 (266) 50.6 (317) 51.6 (363) 41.3 (213) 
Donepezil 47.4 (2,595) 46.0 (2,810) 44.3 (3,045) 43.2 (3,099) 41.7 (2,564) 32.8 (88) 29.6 (145) 30.8 (193) 31.7 (223) 35.7 (184) 
Rivastigmine 8.1 (443) 8.1 (495) 8.7 (596) 8.9 (642) 8.8 (539) 4.9 (13) 6.5 (32) 5.0 (31) 5.5 (39) 6.2 (32) 







Table 11: Prevalence Of Type Of AD Medication Use In Each Year 2004-2008, In Community And Hospital Assessed Individuals With CPS Scores Between 4 And 6 
 
Community Hospital 
  2004 2005 2006 2007 2008 2004 2005 2006 2007 2008 
ChEI 
+Memantine 
1.0 (22) 5.5 (128) 11.2 (248) 12.8 (277) 14.7 (266) 0.0 (0) 1.9 (6) 3.4 (14) 5.8 (27) 4.9 (19) 
ChEI only 52.2 (1,156) 50.8 (1,188) 47.5 (1,052) 48.1 (1,038) 48.3 (877) 45.4 (84) 30.9 (96) 37.4 (153) 38.7 (179) 36.9 (144) 
Memantine 
only 
0.3 (7) 1.5 (35) 2.9 (64) 2.7 (58) 3.2 (58) 0.0 (0) 1.9 (6) 1.5 (6) 3.7 (17) 2.6 (10) 
None 46.5 (1,031) 42.2 (986) 38.5 (852) 36.4 (785) 33.8 (614) 54.6 (101) 65.3 (203) 57.7 (236) 51.8 (240) 55.6 (217) 
Donepezil 36.7 (813) 37.7 (880) 38.2 (847) 36.3 (784) 36.1 (656) 29.2 (54) 21.9 (68) 23.5 (96) 25.1 (116) 26.7 (104) 
Rivastigmine 7.2 (160) 8.1 (190) 8.2 (182) 10.1 (218) 10.4 (189) 8.7 (16) 4.5 (14) 5.4 (22) 6.1 (28) 5.9 (23) 





From 2004 to 2007, the majority of hospital assessed clients with CPS scores between 0 
and 3 received neither ChEIs or memantine. However, in 2008 the majority in that group 
did receive either ChEI or memantine. Among those with CPS scores of 4-6 in the 
community, the majority did receive AD medications in each year studied and use has 
increased over time. In 2004, 53.5% received AD medications and by 2008, 66.2% 
received them. Donepezil was the most commonly received AD medication across all 
years, assessment settings, and CPS scores. 
 
While the prevalence of donepezil and rivastigmine use remained fairly constant across 
the years reported, there was an observed increase in galantamine use in all four 
groups. The largest increase was seen in the community CPS 0-3 group where 12.2% of 





5.5 Multivariate models predicting receipt of AD medications in 
the community sample 
 
Candidate independent variables were entered into a logistic regression model (Table 
12) that predicted the receipt of any AD medication among long-stay Ontario home care 
clients that were assessed in the community. The community sample alone was used 
because the economic tradeoffs item was found to be protective against receiving AD 
medication, but it was not collected in the hospital version of the assessment. Using 
only the community sample allowed that item to remain in the model. 
 
The independent variables that were considered were found to be significant (p<0.05) in 
bivariate testing and included: gender, age group, marital status, living arrangement, 
presence of caregiver distress, CPS, ADL, CHESS, DRS 3+, Pain, congestive heart failure, 
incontinence, hypertension, coronary artery disease, emphysema/asthma/COPD, renal 
failure, economic tradeoffs, no medication oversight, and CCAC where the assessment 
was performed. The crude odds ratios were reported in Table 12. Interactions were 
tested but none were significant at the p<0.05 level so they were not included in the 
model. 
 
The CPS was transformed because it has a curvilinear relationship with receipt of AD. A 
quadratic term (or squared term) for CPS was added to the model described above, in 
which the first order term for CPS was already included. Both the first order term and 




In the final logistic regression model, as shown in Table 12, all of the independent 
variables entered were significant and independently predicted the receipt of AD 
medications except for living arrangement, incontinence, and presence of caregiver 
distress. 
 
Women had  decreased odds of receiving the medications as compared to men  (odds 
ratio =0.89). Those in the 65-74 year old age range had the highest odds of receiving the 
medications, and the odds of receiving them decreased as the age group increased.  
 
With all the scale scores except CPS, which will be discussed later, increasing 
impairment was associated with decreased odds of receiving AD medications. Increasing 
ADL Hierarchy scores, which indicate increasing impairment, were associated with 
decreased odds of receiving AD medications – most dramatically in those scoring 5 or 6 
on the ADL Hierarchy scale. Those individuals had an odds ratio only 0.37 times as high 
as those who scored 0 or 1 on the scale. CHESS scores of 4 or 5 were associated with an 
odds ratio of 0.80 as compared to those with the lowest CHESS scores. A score of 3 or 
more on the DRS indicates a possible depression, and those who scored at that level had 
0.90 times decreased odds of receiving AD medications. The pain scale was entered as 
the full 0-3 range, and so with each unit increase in the scale score, the odds of receiving 




Table 12: Multivariate Model Predicting Use Of Any AD Medication Among Those Assessed In The Community 
  
Crude Odds Ratio 
(95% CI) 





Female 0.79 (0.75-0.84) 0.89 (0.84-0.96) -0.11 0.001 
Age (65-74 = reference)  
   
  75-84 0.88 (0.80-0.96) 0.90 (0.82-0.98) 0.08 <.0001 
  85+ 0.56 (0.51-0.61) 0.63 (0.57-0.69) -0.27 <.0001 
Married 1.43 (1.36-1.52) 1.28 (1.20-1.37) 0.25 <.0001 
CPS
2
  -- 0.41 <.0001 
CPS squared  -- -0.07 <.0001 
ADL (0-1 = reference)  
   
  2-4 0.70 (0.66-0.74) 0.78 (0.73-0.84) 0.17 <.0001 
  5-6 0.22 (0.19-0.26) 0.37 (0.31-0.44) -0.59 <.0001 
CHESS (0-1  = reference)  
   
  2-3 0.90 (0.85-0.95) 0.96 (0.90-1.02) 0.04 0.191 
  4-5 0.60 (0.51-0.71) 0.80 (0.68-0.95) -0.13 0.022 
DRS 3+ 0.90 (0.83-0.96) 0.90 (0.83-0.97) -0.10 0.008 
Pain Scale 0.91 (0.88-0.94) 0.93 (0.90-0.96) -0.07 <.0001 
CAD 0.91 (0.84-0.98) 0.92 (0.85-1.00) -0.08 0.039 
CHF 0.57 (0.51-0.64) 0.67 (0.59-0.75) -0.41 <.0001 
Emphysema/Asthma/COPD 0.86 (0.78-0.95) 0.88 (0.79-0.97) -0.13 0.014 
Hypertension 1.06 (1.00-1.12) 1.07 (1.01-1.14) 0.07 0.016 
Renal Failure 0.58 (0.48-0.70) 0.64 (0.53-0.78) -0.44 <.0001 
No Medication Oversight 0.53 (0.45-0.61) 0.54 (0.46-0.63) -0.61 <.0001 
Made Economic Tradeoffs 0.61 (0.44-0.85) 0.65 (0.46-0.92) -0.43 0.014 
CCAC (Toronto Central = 
reference) 
 
   
  Waterloo Wellington 1.26 (1.09-1.47) 1.14 (0.98-1.33) -0.01 0.834 
  South West 1.40 (1.22-1.61) 1.24 (1.07-1.43) 0.07 0.156 
  South East 1.22 (1.04-1.43) 1.09 (0.92-1.29) -0.06 0.377 
  North West 1.46 (1.18-1.81) 1.27 (1.02-1.59) 0.10 0.289 
  North Simcoe Muskoka 1.44 (1.21-1.71) 1.24 (1.04-1.48) 0.07 0.299 
  North East 1.42 (1.20-1.67) 1.27 (1.07-1.51) 0.10 0.142 
  Mississauga Halton 1.26 (1.09-1.45) 1.25 (1.08-1.45) 0.08 0.127 
  Hamilton Niagara Haldimand 
Brant 
1.18 (1.04-1.33) 1.03 (0.91-1.17) -0.12 0.003 
  Erie St. Clair 1.29 (1.10-1.51) 1.16 (0.98-1.37) 0.00 0.939 
  Central West 1.17 (0.98-1.38) 1.07 (0.90-1.28) -0.07 0.290 
  Champlain 1.32 (1.16-1.50) 1.18 (1.03-1.35) 0.02 0.591 
  Central 1.19 (1.05-1.35) 1.12 (0.98-1.28) -0.03 0.477 
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Of the five diagnoses included in the model (CHF, hypertension, CAD, 
emphysema/asthma/COPD and renal failure) all but hypertension were associated with 
decreased odds of receiving AD medications. Specifically, those with congestive heart 
failure (CHF) had an odds ratio of 0.67. The ‘made economic tradeoffs’ item was also 
protective of receiving AD medications (Odds Ratio=0.65).  
 
There were also important regional differences in the use of these medications. Most of 
the individual p-values were not significant, but the wald chi-square value for the overall 
class variable was 24.9 with 13 degrees of freedom and a p-value of 0.02 so it is 
appropriate to keep the regional variable in the model. The Toronto Central CCAC was 
chosen as the reference group because the odds of receiving AD medications there were 
found to be the lowest among all the CCACs during bivariate testing. As compared to 
Toronto Central, the odds ratio for receiving an AD medication ranged from 1.03 in the 
Hamilton Niagara Haldimand Brant CCAC to 1.27 in the North East and North West 
CCACs.  
 
Goodness of fit calculations indicated good predictive power of the final model. The c-





Figure 1 illustrates the CPS quadratic relationship. It shows the curvilinear relationship 
between CPS and receipt of AD medications by reporting the odds ratio for receiving the 
AD medications separately for each level of CPS. A CPS score of 0 was set as the 
reference category, and the odds increased among those with scores of 1, 2, or 3, then 





































Cognitive Performance Scale Score
67 
 
Separate models were constructed for those assessed in the community with CPS scores 
of 0-3 and for those with scores of 4-6 to see if there were differences in the predictors 
of AD medication receipt between those with mild-moderate AD and more severe 
disease.  
 
The model for those with CPS scores of 0-3 (n=18,000) can be seen in Table 13. It was 
very similar to the full model in Table 12. The only variables that were not significant 
after controlling for all the other items were hypertension and made economic 
tradeoffs. 
 
The 95% confidence limits of the adjusted odds ratios in this CPS 0-3 model all overlap 
with the 95% confidence limits of the full model in Table 12 so the adjusted odds ratios 
were not statistically different than the adjusted odds ratios found in the full model. The 







Table 13: Logistic Regression among those assessed in the community with AD and a Cognitive Performance Scale 
score of 0-3 (n=18,000) 
 
Crude Odds 
Ratio (95% CI) 
Adjusted Odds 
Ratio (95% CI) 
Parameter 
Estimate p-value 
Female 0.81 (0.76-0.87) 0.89 (0.82-0.96) -0.12 0.002 
Age (65-74 = reference) 
      75-84 0.87 (0.79-0.96) 0.91 (0.82-1.01) 0.08 0.001 
  85+ 0.58 (0.52-0.65) 0.65 (0.58-0.72) -0.26 <.0001 
Married 1.43 (1.34-1.52) 1.31 (1.22-1.41) 0.27 <.0001 
ADL (0-1 = reference) 
      2-4 0.78 (0.72-0.84) 0.82 (0.76-0.89) 0.15 0.017 
  5-6 0.35 (0.25-0.49) 0.43 (0.30-0.61) -0.50 <.0001 
CHESS (0-1  = reference) 
      2-3 0.86 (0.80-0.91) 0.93 (0.87-1.00) 0.05 0.196 
  4-5 0.58 (0.47-0.70) 0.75 (0.61-0.92) -0.17 0.013 
DRS 3+ 0.86 (0.79-0.94) 0.89 (0.82-0.97) -0.12 0.011 
Pain Scale 0.88 (0.85-0.91) 0.91 (0.88-0.94) -0.10 <.0001 
CAD 0.84 (0.77-0.91) 0.87 (0.80-0.95) -0.14 0.001 
CHF 0.54 (0.48-0.61) 0.64 (0.57-0.73) -0.44 <.0001 
Emphysema/Asthma/COPD 0.81 (0.73-0.91) 0.86 (0.77-0.97) -0.15 0.010 
Renal Failure 0.57 (0.46-0.71) 0.65 (0.52-0.81) -0.43 <.0001 
No Medication Oversight 0.53 (0.44-0.63) 0.52 (0.44-0.63) -0.65 <.0001 
CCAC (Toronto Central = 
reference) 
      Waterloo Wellington 1.35 (1.14-1.61) 1.29 (1.08-1.54) -0.01 0.888 
  South West 1.51 (1.28-1.77) 1.44 (1.22-1.69) 0.10 0.076 
  South East 1.30 (1.08-1.56) 1.25 (1.03-1.51) -0.04 0.585 
  North West 1.58 (1.25-2.00) 1.55 (1.22-1.97) 0.17 0.083 
  North Simcoe Muskoka 1.51 (1.24-1.83) 1.42 (1.16-1.73) 0.09 0.260 
  North East 1.37 (1.14-1.66) 1.36 (1.12-1.65) 0.05 0.536 
  Mississauga Halton 1.47 (1.24-1.75) 1.44 (1.21-1.72) 0.11 0.098 
  Hamilton Niagara Haldimand 
Brant 1.26 (1.09-1.45) 1.17 (1.01-1.35) -0.11 0.015 
  Erie St. Clair 1.38 (1.14-1.66) 1.30 (1.07-1.57) 0.00 0.972 
  Central West 1.29 (1.06-1.57) 1.23 (1.00-1.51) -0.05 0.503 
  Champlain 1.43 (1.23-1.66) 1.32 (1.13-1.55) 0.02 0.701 
  Central 1.28 (1.10-1.49) 1.23 (1.05-1.43) -0.06 0.244 
  Central East 1.38 (1.18-1.60) 1.30 (1.11-1.52) 0.00 0.984 






The model for those with CPS scores of 4-6  (n=4,977) is shown in  table 14. Many fewer 
variables remained in the model than remained in the CPS 0-3 model. DRS, pain, CAD, 
and emphysema/asthma/COPD were all not significant at the bivariate level so they 
were not entered into the CPS 4-6 model. After controlling for all the other factors 
entered into the model only age, marital status, ADL, CHF, hypertension, renal failure 
and no medication oversight remained significant. The 95% confidence limits for the 
adjusted odds ratios for all the variables in this model overlapped with the 95% 
confidence limits for the adjusted odds ratios in the larger model in table 12. 






Table 14: Multivariable Model Predicting AD Medication use in those assessed in the Community, with AD and a 
Cognitive Performance Scale Score of 4-6 (n=4,977) 
 
Crude Odds 
Ratio (95% CI) 
Adjusted Odds 
Ratio (95% CI) 
Parameter 
Estimate p-value 
Age (65-74 = reference) 
      75-84 0.85 (0.72-1.01) 0.88 (0.74-1.05) 0.102 0.015 
  85+ 0.47 (0.40-0.57) 0.57 (0.47-0.69) -0.335 <.0001 
Married 1.65 (1.47-1.85) 1.31 (1.14-1.50) 0.271 0.000 
ADL (0-1 = reference) 
      2-4 0.68 (0.60-0.78) 0.74 (0.65-0.84) 0.241 <.0001 
  5-6 0.23 (0.18-0.27) 0.26 (0.22-0.32) -0.788 <.0001 
CHF 0.67 (0.53-0.85) 0.74 (0.58-0.95) -0.302 0.017 
Hypertension 1.24 (1.10-1.39) 1.24 (1.10-1.40) 0.214 0.001 
Renal Failure 0.56 (0.37-0.87) 0.58 (0.37-0.91) -0.546 0.019 
No Medication Oversight 0.58 (0.43-0.77) 0.59 (0.44-0.80) -0.528 0.001 










There have been many randomized controlled trials of AD medications, but few studies 
have investigated the utilization patterns in normal clinical practice. This study 
contributes to the literature by being the first to describe utilization of AD medications 
in Ontario home care clients. None so far have described utilization patterns in 
conjunction with individual clinical characteristics in this population. The objectives of 
the study were to: describe those diagnosed with AD in the home care population, 
report the proportion taking AD medications and which types were taken, show the 
change in receipt of AD medications over time, and to show the covariates that are 
independently associated with receiving AD medications. 
6.1 Characteristics of the Sample 
 
The sample of home care clients included was drawn using the first assessments for 
everyone 65 years or older who was a long-stay or hospital-assessed home care client in 
Ontario between January 2004 to September 2008. The prevalence of AD in this sample 
was close to 8%, which is higher than was found in the Canadian Study of Health and 
Aging (Lindsay et al., 2004). This is expected because those already receiving home care 
services are more likely to have illnesses than a random sample of all those over the age 
of 65. Both community and hospital assessed AD groups have a low proportion of clients 
in the youngest age category. This could be expected because of the nature of AD as an 
age-related disease that is much more common among the 75-84 and 85+ age groups 




Clients with AD were more likely to show signs of possible depression and behaviours 
such as wandering and resisting care. The hospital-assessed group had higher 
proportions of clients who were severely impaired in both cognition and activities of 
daily living. As well, those in the hospital scored higher on the CHESS scale and were 
more likely to have incontinence than those in the community. The hospital group also 
had much higher proportions indicating caregiver distress and clients or caregivers 
responding that the client would be better off in a setting different than their normal 
living environment.  
 
With all these differences, it is clear that those assessed in the community and those 
assessed in the hospital are very different populations and it is appropriate to 
investigate them separately. Those who are very severely impaired and whose informal 
caregivers are not able to continue caring for the client safely at home are likely to be 
placed in a Long-Term Care Home and are less likely to appear in the community 
sample.   
6.2 Prevalence and type of AD medication use 
 
When investigating the prevalence of AD medication receipt, clients in the community 
and hospital assessed groups were further subdivided into four mutually exclusive 
subgroups. These subgroups were hypothesized to have different proportions receiving 
AD meds. Those with AD were indeed the most likely to receive any AD medication, and 
the proportion of those receiving any AD medications in the AD groups was almost twice 
73 
 
as high as the proportion receiving them in the respective community and hospital 
‘other dementia’ groups. This shows that a diagnosis of AD is a driving factor for 
receiving AD medications, and is also evidence for the validity of the AD diagnosis on the 
assessment itself.   
 
One may wonder why those with other dementia are receiving AD drugs. It is true that 
they are only indicated for use in AD, except for rivastigmine which received approval 
from Health Canada in late 2007 to add Parkinson’s disease with mild-moderate 
dementia to the list of indications (Health Canada, 2007). However, there are reports of 
ChEIs being tested in randomized controlled trials for use in vascular and Lewy body 
dementias, and also in traumatic brain injury, with results showing improvement in 
various cognitive and functional scales (Kaye et al., 2003; McKeith et al., 2000; Wilkinson 
et al., 2003). Memantine has also been investigated for use in vascular dementia 
(Orgogozo et al., 2002). With these sorts of reports published in the literature, 
physicians may be prescribing ChEIs and memantine for these other types of dementias. 
 
Donepezil is the ChEI that is used most often in all the groups that were studied. Some 
possible explanations are that it was the first medication approved in Canada. 
Consequently, it is most familiar to physicians and it is the drug with the largest body of 
evidence. On the other hand, it is indicated for mild-moderate and moderate-severe AD, 
while the other two ChEI medications are only indicated for mild-moderate AD. 




The vast majority of those who receive any ChEIs receive only one because the 
mechanisms of action are very similar, so it is not advisable to take more than one at 
once (Birks, 2006). However, the assessor does record all medications that were taken in 
the seven days before the assessment date during the assessment process and it is 
possible that a switch from one type of ChEI to the other could have taken place within 
the 7-day window. Therefore, the presence of clients who are taking multiple AD 
medications may be explained, at least in part, by transitions in prescriptions. 
 
Clients that were assessed in the hospital show an overall lower proportion of receipt of 
AD medications. This could be because ChEIs and memantine are used to stabilize and 
slow down the onset of symptoms of AD, and as such they may be described as 
preventive care. Those whose first RAI-HC assessments are in the hospital may be less 
likely to have sought preventive care with a family physician as well as not having sought 
HC services. Alternately, some medications may be discontinued while the person is in 
the hospital. 
 
There was a higher proportion of high CPS scores among hospital assessed clients. Those 
who are severely cognitively impaired are likely not living in the community because 
their informal caregivers are not able to care for them safely and therefore these 
individuals do not appear in the community assessed sample. The curvilinear patterns 
seen in the proportion of those in the lowest to highest CPS levels among both the 
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community and hospital groups with AD show that clients with all CPS levels do receive 
AD medications. However, the groups with the least and most impaired cognition have 
the lowest proportions receiving them.  
 
The Ontario Drug Benefit program allows access to ChEIs for individuals whose MMSE is 
10-28. This range of MMSE scores corresponds to CPS scores of 0 (intact) to 3 
(moderate) and is often used as an indication of mild-moderate AD. Clients with AD and 
a CPS score of 0-3 are significantly more likely to receive AD medications than those 
with higher CPS scores. This is an expected finding because all three ChEIs have been 
indicated for use in mild-moderate AD for the entire time period studied. It was not until 
2007 that donepezil had its indication expanded to include moderate-severe AD. 
Memantine use is higher in those with moderate-severe AD, but it is still rare when 
compared to ChEI use. This is likely due to the relatively recent availability of 
memantine, as well as the fact that it is not available through the ODB. 
 
In the community, almost 60% of clients with CPS scores of 4-6 are receiving AD 
medications. There is evidence for use of donepezil in moderate-severe AD, so such 
prescribing is supported by currently available literature (Feldman et al., 2001; Winblad 
et al., 2006). Based on ODB guidelines, those with moderate-severe AD would not 
receive ChEIs through the provincial formulary, so it is surprising that the prevalence of 
receipt is so high. Perhaps reluctance to discontinue the medications can result in clients 
continuing to receive AD medications after they progress to the moderate-severe stage 
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of AD. Also, in practice, MMSE scores from the physician are not always required in 
order for the prescription to be filled through ODB, making the guidelines difficult to 
enforce. These speculations cannot be verified in publically available sources, but could 
explain the large numbers of people with moderate-severe AD receiving the 
medications.  
6.3 Changes over time in receipt of AD medications 
 
The most striking changes over time in receipt of AD medications involve memantine. 
The time period of this study coincided with its introduction to the Canadian market in 
late 2004, so the uptake of this medication in its first four years is clearly evident. The 
rise in use is seen mostly among those with AD in the community with CPS scores of 4-6. 
This is expected because memantine is indicated for more severe AD. Use of ChEIs alone 
tended to decrease across the time period, while use of the combination of a ChEI and 
memantine increased. This is evidence of appropriate prescribing because the two types 
of medications have different mechanisms of action and have been shown to work well 
together (Tariot et al., 2004). 
 
 The largest differences in ChEI use between 2004 and 2008 were seen in the ‘other 
dementia’ groups in both community and hospital settings, which may reflect the 
growing body of evidence for use of ChEIs in other dementias.  
 
Donepezil’s indication was expanded in 2007 to include those with moderate-severe AD 
so we would expect to see an increase in use in 2008 among those with CPS 4-6. An 
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increase in donepezil use was not observed between 2004 and 2008 in community 
assessed clients with AD and a CPS score of 4-6, but use did stay fairly stable in that 
group while it dropped over the same time span in the CPS 0-3 group. That drop also 
coincided with an increase in galantamine use, so those in the CPS 0-3 group may be 
more likely to switch to galantamine, while those in the CPS 4-6 group may be more 
likely to remain on donepezil.  
6.4 Covariates independently associated with AD medication 
use 
 
The multivariate model shows which individual characteristics are independently 
associated with receipt of AD medications among those with AD who were assessed in 
the community. Women had decreased odds of receiving AD medications. This could be 
evidence of systematic undertreatment of women; however, it has been reported that 
women are more likely to have adverse events such as nausea and vomiting, possibly 
due to their generally lower body weight  (Birks, 2006). Therefore, the decreased odds 
of receiving the medications could be due to them being previously tried and 
discontinued due to adverse events, or a reluctance to initiate for fear of those same 
events. If body mass index were included in the assessment, then low body weight could 
be controlled for. 
 
Those in the 75-84 and 85+ age groups also had decreased odds of receiving AD 
medications and the odds were lowest among the oldest clients. Physicians may be 
reluctant to prescribe AD medications to this oldest age group because of lack of 
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perceived potential benefit to those who are older as compared to younger patients 
with AD. Frailty (as measured by the CHESS scale) and the major comorbid conditions 
have been controlled for in the model.  
 
Clients who were married had odds of receiving AD medications that were 1.28 times 
higher than those who were not. This is likely a reflection of the importance of an 
informal caregiver who may be available to advocate for medication receipt on behalf of 
the client with AD. 
 
The curvilinear relationship of CPS scores with receipt of AD medications is expected, 
because the medications are likely not yet prescribed at the low end of CPS and are not 
shown to be as effective at the highest CPS scores. These medications are supposed to 
be used for stabilization and maintenance of cognitive function, so it is surprising that 
only those with a CPS score of 6 had an odds ratio less than one when compared to the 
reference group of clients with CPS scores of 0.  
 
Higher ADL Hierarchy scores were associated with lower odds of receiving AD 
medications. This could be a reflection of a reluctance to prescribe AD medications 
when the risks of side effects may outweigh the benefits of preserving the level of 
physical function that currently exists. ADL impairment could be considered to be a sign 




Higher CHESS scores, which indicate increased clinical complexity, are also associated 
with decreased odds of receiving AD medications and this could be due to competing 
priorities for physicians. If there are other more critical health problems aside from the 
comorbidities controlled for in the model that need to be dealt with, then prescription 
of AD medications may not be a priority.  
 
Clients with a DRS score of 3 or more, which indicates possible depression, and those 
with higher pain scores have slightly decreased odds of receiving AD medications. As 
was evident for the CHESS score, this may also be influenced by competing clinical 
priorities.  
 
Diagnoses of CAD, CHF, renal failure and emphysema, asthma, or COPD meant that 
clients had decreased odds of receiving AD medications. This is to be expected because 
in the prescribing guidelines physicians are instructed to be cautious in using the 
medications in individuals with these conditions. The effects are not all the same for 
these diagnostic groups. Clients with CHF and renal failure had odds ratios in the 0.60 
range, while those with CAD and the airway diseases had odds ratios in the 0.90 range. 
This suggests that physicians were more cautious in light of more serious comorbidities.  
 
Clients with no medication oversight – no one physician had reviewed all their 
medications in the last six months – had greatly decreased odds of receiving AD 
medications when compared to those who had had a medication review. This is likely 
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reflective of lack of contact with a physician and therefore lack of opportunity to be 
prescribed the medications.  
 
Those who made economic tradeoffs, which is an item used as a proxy for low income, 
had odds of receiving AD medications that were 0.65 times lower than those who did 
not have to make those tradeoffs. A positive response to the economic tradeoffs item is 
very rare in this population – only 0.6% reported it – so it is surprising that it is 
significant in the multivariate model. This finding could be explained in several ways. It 
could be a social class effect where those with low income are less likely to be involved 
with physicians for preventive care. It could also be a resource issue where clients may 
wish to be in contact with a physician, but issues of access such as lack of transportation 
to the physician or to the pharmacy discourage medication use. It could be that the 
medication was prescribed and transportation was possible, but the required ODB co-
payment of $2 per prescription was too onerous and other medications were prioritized. 
Finally, it could be that wealthier individuals receive the AD medications through private 
insurance or out-of-pocket payments even though they may not be eligible through 
ODB.  
 
CCACs are the main unit of organization for Ontario’s home care system. After all the 
individual clinical characteristics have been controlled for, those clients in the Toronto 
Central CCAC had the lowest odds of receiving AD medications. Toronto Central is a 
geographically small CCAC which is completely urban and has very high population 
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density. Clients residing in six of the 13 other CCACs had significantly greater odds of 
receiving AD medications when compared to those residing in Toronto Central. These 
CCACs were Champlain, South West and North Simcoe Muskoka (tie), Mississauga 
Halton, North East and North West (tie), in order of lowest to highest odds ratios. The 
most obvious pattern in these results is that the four most northern CCACs (North East, 
North West, North Simcoe Muskoka and Champlain) were among those that had higher 
odds ratios. It is unclear why the South West and Mississauga Halton CCACs showed 
higher odds ratios.   
 
The models that were stratified based on CPS score showed many of the same variables 
as the full model.  In fact, no new variables were significant in either model.  The 
differences between the full and stratified models were that in the CPS 0-3 group, 
hypertension and economic tradeoffs were no longer significant. In the CPS 4-6 model, 
many fewer variables stayed in the model and only age, marital status, ADL, CHF, renal 
failure, hypertension and no medication oversight were significant. 
 
A potential reason that the CPS 0-3 model is so similar to the full model is that 18,000 of 
the 22,977 clients in the AD group had CPS scores of 0-3 so they made up the majority of 
the cases in the full model.  In the CPS 4-6 model, there were fewer clients (n=4,977) so 





Non-patient determinants of medication use are likely also important predictors of 
whether a client receives AD medications or not. There is qualitative evidence that 
physician attitudes and expectations influence prescription of medications generally 
(Spinewine et al., 2005). A survey of Canadian family physicians found that reporting a 
lack of knowledge of AD medications, perceiving them to be ineffective, being a female 
physician, and lacking formulary coverage in the province were all associated with 
reduced prescribing rates of AD medications (Hillmer et al., 2006). Drug representative 
visits were associated with differing drug prescription patterns, but this was mostly 
related to the brand prescribed and not the category (Sondergaard et al., 2009).  
 
Physician interpretation of patient expectations for prescription was shown to have an 
effect on prescription outcome (Lado et al., 2008). Since family members would likely be 
more involved with prescription of AD medication, it is possible that family factors such 
as attitudes towards physicians and actions such as advocacy for or against AD 
medications could affect receipt of the medications. 
 
These physician and family factors are not measured in the RAI-HC dataset so it is likely 
that their absence from the models decreased the goodness of fit. However, it is 
debatable whether it is appropriate that these physician factors should have a large 








There are limitations in this study that should be noted. The AD groups were created 
using the AD diagnosis checkbox on the RAI-HC assessment. Some may argue that it is 
not sensitive to the complicated nature of AD diagnosis, which is often mixed with other 
dementias. However, due to the professional nature of the assessors, the risk of a 
person being coded as having AD without a firm diagnosis from a physician is low. There 
is evidence that the diagnoses that are recorded on these assessments do correspond to 
hospital discharge information. Specifically, an MDS diagnosis of Alzheimer’s disease 
compared with a recent hospital claim had a positive predictive value of 0.68 (Gambassi 
et al., 1998). In a more recent study conducted on Ontario Complex Continuing Care 
(CCC) patients, results suggested that when AD was listed as the primary diagnosis on 
the hospital discharge abstract immediately preceding the admission to the CCC bed, AD 
was listed on the RAI assessment with a sensitivity of 0.67 (0.64-0.70). When the 
discharge abstract form listed AD as any diagnosis and the presence of  either AD or 
other dementia on the MDS was calculated, the sensitivity increased to 0.85 (Wodchis, 
Naglie & Teare, 2008). 
 
The medication data that are used in this study are collected for the seven day period 
before the assessment date. It is not possible to determine a client’s historical use of 
medications so those who were on the medications previously and have since 
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discontinued as well as those who have never received the medications are put together 
in the same group. This could have implications for the multivariate models, as 
covariates that predict discontinuation as well as those that predict never use could be 
important. The attitudes and expectations of clients, informal caregivers and physicians 
could also have an impact on whether or not a person receives an AD medication. That 
information is not available in this dataset. 
 
The cross-sectional nature of the analytic sample used in this study means that the cases 
of AD that were identified are prevalent cases, not incident cases. The first assessment 
for all clients was used, but those who were not assessed using the RAI-HC were not 
represented in the sample. Because this study used prevalent cases it is not possible to 
establish a temporal order between the clinical characteristics of the clients and the 
receipt of AD medications. 
 
Survivor bias, which can result from only following up on those who are still alive and 
able to be assessed, can underestimate incidence rates of AD in longitudinal studies 
(Tyas et al., 2006). It can also have implications for cross-sectional studies because 
individuals with rapidly progressing disease may die and are not available to be assessed 
(Zhou, Rahme, Abrahamowicz & Pilote, 2005). In this study, those with rapidly 
progressing dementia may die before receiving HC services and would therefore not be 




The Ontario HC dataset represents long-stay home care clients only. These are a large 
subset of the Ontario Home Care population, but they do not necessarily represent all 
home care clients. However, those with dementia that are receiving home care services 
do tend to be long-stay clients so the dataset likely does cover most of the population of 
interest. Those who are not receiving long-term home care services may be receiving 
community support services. These individuals could be assessed with the interRAI 
Community Health Assessment (CHA), which is an assessment designed for community 




One of the main strengths of this study is the dataset itself. The large sample size – over 
300,000 records – and the breadth of clinical data available allows identification of 
specific rare subpopulations. Domains such as cognition, communication, and mood and 
behaviour patterns are assessed, as well as functional status, informal caregiving 
support, disease diagnoses, and many other clinically significant areas. 
 
 The client is always assessed by a trained professional who is usually a registered nurse. 
The data are used in many different ways in the Ontario home care sector. They are 
primarily used for care planning for the individual, but also for quality indicators and 
administrative planning so there is an incentive for both administrators and front-line 




Another strength of the dataset is the nature of the medication information. It is 
collected by the assessor at the person’s home, so all medications are collected 
including over the counter and private insurance pay (not just those offered by ODB). 
Unlike the ODB administrative dataset, which reports the medications dispensed at the 
pharmacy level, the RAI-HC medication information reflects what was actually taken by 
the person over the seven days before the assessment. 
 
The RAI-HC is a comprehensive assessment, and it is standardized so it is comparable 
across jurisdictions. All those who begin to receive HC services and who are expected to 
remain on-service for 60 days or longer receive an assessment, and continue to receive 
one every six months as long as they remain on-service. Thereforeit is census-level 
information for that group. Service utilization and discharge information is available for 
this dataset, though it is not used for these analyses. 
 
6.6 Future research 
 
In the future these analyses could be replicated across different jurisdictions and in 
different care settings. The Canadian Institute for Health Information has recently set up 
the Home Care Reporting System (HCRS), and several provinces are submitting their RAI-
HC assessments. Once data are available, researchers can compare utilization and 
predictors of AD medication use across provinces as well as investigate implications of 
different policy decisions such as regulations for access to AD medications through 




It would also be interesting to look into the use of AD medications in other sectors that 
support people with AD such as long-term care homes, complex continuing care and 
inpatient mental health. Comparable studies could be carried out in both these sectors 
in Ontario because people in all three sectors are assessed using interRAI assessments 
so many of the items in each assessment are comparable to those in the HC assessment 
used in this study. A long-term care or complex continuing care study would need to use 
a cross-sectional sample from a research project that is currently being carried out, 
because completion of the medication section is not yet mandated in those settings. 
Data on those in geriatric psychiatry beds from the Ontario Mental Health Reporting 
System could be used to carry out a comparable study in the inpatient mental health 
setting. 
 
Cross national comparisons can also be done among countries that use the same 
instruments and also collect medication information. The interRAI family of instruments 
have been used extensively for international comparisons, most notably in the 11 
country Aged in Home Care (AdHOC) study based on the RAI-HC (Carpenter et al., 2004; 
Cooper et al., 2005; Fialova et al., 2005; Sørbye et al., 2009). 
 
Other types of questions would also be of interest. Investigation into concurrent use of 
ChEIs and anticholinergics or benzodiazepines would be helpful to determine the extent 
of use of contraindicated medications. It would also be interesting to develop a 
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multivariate model to predict the use of AD medications among the ‘other dementia’ 
group and see if the predictors were the same as the ones found in the current study. 
Longitudinal analyses would be the next important step. Discharge information is now 
available up to September 2008, so trajectories of disease as measured by changes in 
scale scores over time could be studied as well as time to nursing home placement. 
 
6.7 Policy Implications 
 
The major policy implication involves the ODB and the availability of subsidized 
medications for those over the age of 65. This study showed that many home care 
clients are receiving AD medications when ODB guidelines would likely restrict their 
reimbursement. The available data do not allow a determination of which clients have 
received medications through the ODB and which obtained them through private 
means. However, it seems unlikely that all the clients with CPS scores of 4-6 are 
obtaining the medications through private means, as the prevalence of memantine use 
by 2008 was still low when compared to ChEI use, and memantine is not listed on the 
formulary.  
 
Since those who do not have to make economic tradeoffs were found to be more likely 
to receive AD medications it is possible that people with no economic alternatives faced 
systematic barriers to receiving them. Those with CPS scores of 4-6 were less likely to 
receive the medications because of the stage of their disease, however some of these 
individuals continued to receive the medications perhaps because they, their caregivers 
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or their physicians were insistent. This could possibly have been facilitated by weak 
regulations based on MMSE scores.  
 
Also, donepezil and memantine have been approved for use in moderate-severe AD and 
have been shown to be useful in RCTs, so consideration should be made to expanding 
the limited use guidelines, and possibly including memantine on the formulary. 
However, choices about which medications should be covered must always be made 
and economic analyses could be performed to see if it is in the public interest to cover 
these medications.  
 
Use of these medications has been reported to delay time to nursing home placement, 
which would be an important cost consideration (Geldmacher et al., 2003). However, 
with delayed nursing home placement comes a need for more supports for informal 
caregivers. This would need to be considered in the economic analyses, but it would 
serve the needs of clients who wish to remain in their homes, and caregivers who desire 
to support them there for as long as possible. 
 
6.8 Conclusions  
 
The majority of home care clients who are diagnosed with AD do receive an AD 
medication and a much smaller proportion of those diagnosed with other dementias 
receive them as well. Donepezil is the ChEI that is used most often among all the groups. 
The use of ChEIs has not increased very much from 2004-2008, but the use of 
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memantine has grown substantially. Multivariate analysis showed trends of rational 
prescribing, such as clients with contraindicating diagnoses or very high clinical 
complexity being less likely to receive AD medications. At the same time, it also showed 
evidence of structural barriers to receipt of the medications, such as having to make 
economic tradeoffs and the CCAC where the person resides.  
 
This multivariate model contributes to the body of knowledge about AD medication use 
in the Ontario home care population, specifically by linking clinical characteristics to 
receipt of AD medications. These analyses also show that the population using these 
medications is quite different than the population represented in most randomized 
controlled trials. In future, research using the RAI-HC  dataset has the potential to 
measure real-world results of treatment in terms of changes in cognitive and physical 
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Limited access to all ChEIs 
Requirements: 
 MMSE 10-26 
 GDS 4-6 
 
Initial authorization for 6 months 
Renewal requires form, algorithm to be completed 
Available, but not 
through provincial 
formulary 
Alberta Limited access to all ChEIs 
Requirement: 
 MMSE 10-26 
 
Initial authorization for 12 weeks 
Renewal requires MMSE drop less than 3 points in 12 
weeks 
Available, but not 
through provincial 
formulary 
Saskatchewan Limited access to all ChEIs 
Requirements: 
 Diagnosis of probable AD 
 MMSE 10-26 
 FAQ score 
 Discontinuation of drugs with marked 
anticholinergic activity 
 
Initial authorization for 3 months 
Renewal requires improvement in MMSE (+2 points) 
or FAQ score (-1 point) 
Available, but not 
through provincial 
formulary 
Manitoba Limited access to all ChEIs 
Requirements: 
 Confirmed AD diagnosis (DSMIV) with 
memory impairment and one of aphasia, 
apraxia, agnosia, disturbed executive 
function. 
 The deficits must have caused significant 
gradual and continued decline, are not due 
to other conditions, and do not occur only 
during delirium. 
 Normal test results for CBC, TSH, 
Electrolytes, VitB12 and glucose 
 MMSE score between 10-26 measured 
within 30 days of application 
 
Initial authorization for 3 months 
Renewal requires MMSE score of 10 or higher 





Ontario Limited access to all ChEIs 
Requirements: 
 Diagnosis of AD 
 MMSE score 10-26 
 
Initial authorization for 3 months 
Renewal requires  MMSE of 10 or higher 
Available, but not 
through provincial 
formulary 
Quebec Limited access to all ChEIs 
 MMSE 10-26 
 Global evaluations of cognition, function, 
behaviour and social interactions 
 
Initial authorization for 6 months 
Renewal requires an MMSE of 10 or higher, 
maximum drop of 3 points on MMSE or significant 
improvement on evaluations of cognition, function, 
behaviour and social interactions  










Limited access to all ChEIs 
Requirements: 
 Diagnosis of probable AD or possible AD with 
vascular or Lewy bodies 
 MMSE 10-30 
 FAST 4-5 
 Target symptoms in each of three domains 
(out of cognition, function, behavior, 
social/leisure) 
 
Initial authorization for 6 months 
Renewal requires: 
 Stabilization or improvement in one target 
symptom (90 day continuation) 
 MMSE 10-30 and FAST 4-5 and stabilization 
or improvement in at least one target 
symptom (6 month renewal, if renewed at 6 
months then annual renewal) 


























Local Health Integration Networks (LHIN) Characteristics: LHINs 1-7 
 
  Ontario avg 1 2 3 4 5 6 7 












Major city N/A Windsor London Kitchener Hamilton  Brampton  Mississauga  Toronto 
Population 12,160,282  630,195  901,123  686,324  1,315,964  739,957  1,008,004  1,090,301  
2001 -06 pop. change (%)  6.6 3.4 3.6 8.4 4.3 18.1 12.1 -0.3 
% of Ontario population N/A 5.2 7.4 5.6 10.8 6.1 8.3 9.0 
Population density 13.4 86.1 43.1 144.6 203.3 285.7 956.7 5679.0 
Total size (Km^2) 907,574  7,324  20,904  4,747  6,473  2,590  1,054  192  
% Rural 14.9 20.1 28.5 12.1 11.9 6.8 2.1 0.0 
% Age 65+ 13.2 14.5 15.2 12.0 15.8 9.4 10.9 13.0 
% Aboriginal 2.0 2.4 1.4 0.7 1.4 0.6 0.4 0.8 
% Low income 14.7 12.2 11.1 9.8 13.8 14.6 13.3 24.2 
Median income in 2005, 
all private households ($) 
60,455  57,456  55,105  64,915  57,610  69,645  75,881  52,319  
% Received influenza 
shots in the past year 
36.6 40.1 39.2 35.6 33.5 35.3 31.9 32.7 
% Contact with medical 
doctor in the past year 
81.6 81.7 79.0 80.5 80.8 84.9 85.0 83.0 
# of Community hospitals 60 5 7 5 5 2 3 2 
# of Small hospitals 34 0 5 1 2 0 0 0 




Local Health Integration Networks (LHIN) Characteristics: LHINs 8-14 
 
  Ontario avg 8 9 10 11 12 13 14 
LHIN Name N/A Central Central East South East Champlain North 
Simcoe 
Muskoka 
North East North West 




Population 12,160,282  1,532,649  1,432,695  466,669  1,147,209  422,902  551,691       234,599  
2001 to 2006 population 
change (%)  
6.6 13.3 6.3 3.2 4.3 12.2 -0.3 0.6 
% of Ontario population N/A 12.5 11.0 3.8 9.4 3.5 4.5 1.9 
Population density 13.4 561.3 93.8 26.1 65.1 50.5 1.4 0.6 
Total size (Km^2) 907,574  2,730  15,274  17,887           17,631  8,372  395,577       406,820  
% Rural 14.9 4.7 14.0 45.7 20.6 32.7 30.2 36.3 
% Age 65+ 13.2 12.6 13.7 17.2 13.2 15.2 16.5 14.1 
% Aboriginal 2.0 0.4 1.2 2.7 2.0 3.3 9.4 19.6 
% Low income 14.7 17.7 16.1 11.9 13.8 9.7 12.8 10.7 
Median income in 2005, 
all private households ($) 
60,455  75,881           61,114  52,454           64,555  59,148  49,592         54,111  
% Received influenza 
shots in the past year 
36.6 35.5 37.6 41.7 45.8 32.2 39.1 34.2 
% Contact with medical 
doctor in the past year 
81.6 83.4 80.8 78.9 82.0 78.2 79.1 74.2 
# of Community hospitals 60 4 6 3 6 5 5 2 
# of Small hospitals 34 1 1 1 6 0 9 8 
# of Teaching hospitals 16 1 0 1 3 0 1 1 









Appendix D: RAI-HC Assessment Instrument 
(Because of copyright considerations, the assessment instrument cannot be reproduced 
in the electronic version of this thesis. It can be obtained by contacting Dr. John P. 
Hirdes at the University of Waterloo) 
 
 
 
